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Abstract 
 
Characterisation of N-terminal fragments of Retinoblastoma Binding Protein 6  
for structural analysis 
 
P. Maumela, MSc (Biotechnology) Thesis, Department of Biotechnology, Faculty of Science, 
University of the Western Cape 
 
Retinoblastoma Binding Protein 6 (RBBP6) is a 200 kDa RING finger-containing protein that 
plays a role in 3’-end poly-adenylation of mRNA transcripts as well as acting as an E3 
ubiquitin ligase against a number of proteins involved in tumourigenesis, including p53. 
Since the human protein is too large and poorly structured for heterologous expression in 
bacteria, it would be advantageous to identify smaller fragments suitable for expression in 
bacteria. Many E3 ubiquitin ligases form homo-dimers and dimerisation is important for 
their activity; structural studies of the isolated RING finger of RBBP6 showed that it forms a 
weak homo-dimer. This poses the question of whether the complete RBBP6 protein forms 
homo-dimers in vivo, and, if so, whether a fragment of RBBP6 containing the RING finger 
could be identified which would be suitable for structural as well as functional studies. Such 
a construct would allow detailed investigation of the homo-dimeric state of the fragment, 
the relationship between dimerisation and ubiquitination activity, and the role of domains 
such as the DWNN domain and zinc finger in ubiquitination. 
 
A fragment consisting of the first 335 residues of RBBP6, dubbed R3 because it contained 
the first three domains of the protein, was expressed, along with three variants expressing 
mutations known to disrupt the dimerisation of the isolated RING finger. Size exclusion 
chromatography showed that R3 forms a strong homo-dimer that was not disrupted by the 
mutations, suggesting that additional parts of R3 outside of the isolated RING finger form 
part of the interface. To identify whether this included the DWNN domain or the zinc finger, 
a shorter fragment dubbed R2, excluding the N-terminal DWNN domain, was cloned and 
expressed. This was also found to form a strong homo-dimer, suggesting that the DWNN 
domain may not form an essential part of the dimer interface. 
 
 
 
 
  
II 
 
Availability of the RING finger samples and monomerising mutations allowed investigation 
of whether the RING finger from RBBP6 was able to auto-ubiquitinate itself. Using a fully in 
vitro ubiquitination assay supplemented with intact proteasomes purified from human cell 
lysates, we found that wild type RING auto-ubiquitinates itself very efficiently, catalysing its 
own destruction in the proteasome. This provides an answer to the question of why RBBP6 
is so difficult to detect in mammalian cells. Surprisingly, monomeric mutant RING fingers 
were also able to auto-ubiquitinate and catalyse their own destruction, although perhaps 
not as efficiently as wild type. This result would appear to rule out the hypothesis that 
dimerisation of RBBP6 is required for ubiquitination activity. Finally, samples of the RING 
finger from human MDM2 were expressed in bacteria and used to investigate whether the 
RING fingers of RBBP6 and MDM2 interact directly with each other. If so, this may provide a 
mechanism whereby RBBP6 and MDM2 cooperate in ubiquitination of p53. The results of a 
GST pull down assay using GST-MDM2-RING as “bait” and RBBP6-RING as “prey” provides 
evidence that such an interaction between the RING does exist. This work lays the 
foundation for future structural studies of the RING-RING hetero-dimer using protein 
Nuclear Magnetic Resonance Spectroscopy. 
 
Keywords: Cancer, RBBP6, MDM2, p53, ubiquitination, proteasome, size exclusion 
chromatography, GST pull down, Western Blot 
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Chapter 1: Literature Review 
 
1.1 Gene structure and domain structure of RBBP6 
Fragments of Retinoblastoma Binding Protein 6 (RBBP6) were independently identified by 
different groups and given a number of different names: Retinoblastoma Binding Q protein 
1 (RBQ-1) corresponds to residues 150-1146, p53-associated cellular protein testes derived 
(PACT) corresponds to residues 207-1792, and proliferation potential-related protein (P2P-R 
or PP-RP) corresponds to residues 199-1792 of the 1792-residue human protein (Sakai et al. 
1995, Simons et al. 1997; Witte and Scott 1997).  
 
In humans, the single copy RBBP6 gene is found on chromosome 16p12.2 encoding for three 
protein isoforms due to alternative splicing and poly-adenylation (Sakai et al. 1995; Gao and 
Scott 2002; Gao et al. 2002). Three mRNA transcripts of this gene are expressed, namely, 
1.1, 6.0, and 6.1 Kb transcripts. The 6.1 kb transcript encodes the longest isoform of 1792-
residues known as isoform 1; isoform 2 corresponds to an alternative splicing transcript of 
6.0 kb and codes for a protein of 1758-residues. The 1.1 kb transcript is expressed from an 
alternative promoter and codes for a 118-residue protein known as isoform 3. The 
respective sequences of the different isoforms are Genbank: NP_008841, Genbank: 
NP_061173 and Genbank: NP_116015. 
 
RBBP6 orthologues are found in all eukaryotes, but not in prokaryotes. RBBP6 is a multi-
domain protein; the organization of the domains in different eukaryotic organisms is shown 
in Figure 1.1. A minimal isoform containing the three N-terminal domains, the DWNN 
domain, the zinc knuckle, and the RING finger, is found in all RBBP6 orthologues (Pugh et al. 
2006). In higher eukaryotes such as human, RBBP6 isoforms contain additional C-terminal 
domains, including an SR-like domain, as well as domains identified in humans as binding 
pRb and p53 respectively (Witte and Scott 1997; Simons et al. 1997; Yoshitake et al. 2004; 
Pugh et al. 2006).  
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Figure 1.1: Domain structure of Retinoblastoma Binding Protein 6 (RBBP6). The first three N-
terminal domains - the DWNN domain, zinc finger and RING finger - are found in all RBBP6 
homologues, including human, plants, worm, fly, fungi, protists, and microsporidia. In humans, 13 
kDa DWNN is also expressed independently, including a C-terminal tail not present in the full-length 
protein. Additional domains to the first three N-terminal domains, including the SR-like domain, RB 
binding domain, p53 binding domain and nuclear localization signal are found in higher eukaryotes 
such as human (Pugh et al. 2006).  
 
1.2 The role of RBBP6 in mRNA processing 
RBBP6 forms part of the cleavage and poly-adenylation factor complex in yeast and the pre-
mRNA 3’-end processing complex in humans (Vo et al. 2001; Shi et al. 2009). Post-
transcriptional cleavage of mRNA precursors is an essential step in the synthesis of 
functional eukaryotic mRNAs. Following cleavage, most eukaryotic mRNAs acquire a poly(A) 
tail at their 3’-ends. Poly(A) tails are directly implicated in the regulation of gene expression 
because they have a profound influence on the stability, export, and translation efficiency of 
mRNAs. Large pre-mRNA 3’-end processing complexes are required to reconstitute the 
complete poly-adenylation process (Colgan and Manley 1997; Zhao et al. 1999). Along with 
other proteins, including WDR33 (a WD40 repeat-containing protein and a putative 
mammalian homologue of the yeast 3’-end processing factor Pfs2) and PP1 
(serine/threonine phosphatase), RBBP6 is implicated in mRNA 3’-end processing in 
mammals and is a known homologue of yeast 3’-end processing factor Mpe1. Mpe1 is a 
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subunit of the cleavage and poly-adenylation factor (CPF) complex. This complex is 
responsible for the specific cleavage and poly-adenylation of pre-mRNA (Vo et al. 2001; Shi 
et al. 2009).  
 
Like RBBP6, Mpe1 contains the DWNN domain, the zinc knuckle and the RING finger. The 
DWNN domain of Mpe1 is essential for the association of Mpe1 with CPF and CF IA and the 
RING finger contributes to the interaction with CPF but not to that with CF IA. While the zinc 
knuckle of Mpe1 or the second linker region also makes contact with other CPF subunits. 
These three domains are needed for optimal cell growth and function in mRNA 3’-end 
processing. Both the zinc knuckle and RING finger domains are essential for efficient binding 
of Mpe1 to RNA (Lee and Moore 2014).  
 
RBBP6 is significantly larger than Mpe1 and contains additional domains, including an 
arginine/serine-rich (RS) domain that is found in many splicing factors. The ubiquitin-like 
DWNN domain of RBBP6 has been shown to interact with two of the seven core splicing 
proteins, SmB (Simons et al, 1997) and SmG (Pugh et al. 2006, Kappo et al. 2012). RBBP6 
may link mRNA 3’-end formation to the Rb/p53 pathways and tumorigenesis (Shi et al. 
2009). RBBP6 and isoform 3 (DWNN) regulate the 3’-end processing of RNAs with AU-rich 39 
un-translated regions (UTRs) such as c-Fos and c-Jun. Unlike RBBP6-N, a fragment containing 
only the DWNN domain, zinc knuckle and RING finger, a derivative (ΔDWNN) lacking the 
DWNN domain was unable to reconstitute cleavage activity, indicating that the DWNN 
domain is essential in 3’-end processing. However, DWNN inhibits the binding to RNA 
because ΔDWNN shows enhanced RNA-binding affinity. Isoform 3 outcompetes RBBP6 for 
binding to CstF, thus inhibiting cleavage of SVL pre-mRNA (Di Giammartino et al. 2014). 
 
The tertiary structure of DWNN is almost superimposable onto ubiquitin, suggesting that 
DWNN may act as an ubiquitin-like modifier (Pugh et al. 2006). As the first step in the 
process of ubiquitination, a specific protease recognizes the cleavage site between the two 
glycines in the C-terminal GG motif of ubiquitin. The same GG motif is found in exactly the 
same position in DWNN (residues 78 and 79) as it is in ubiquitin-like domains (Yamada et al. 
2012). Interestingly, DWNN is expressed in vertebrates both as a single domain protein of 13 
kDa, known as isoform 3, and as the N-terminal domain of the full length RBBP6 isoforms 1 
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and 2. In addition to the 81-residue DWNN domain, the 118-residue isoform 3 also contains 
a C-terminal tail, which is not found in the full-length protein. In humans, the sequence 
encoding the short tail is poorly conserved across species and unstructured, and is highly 
susceptible to proteolysis when expressed recombinantly in bacteria. The domain is stable 
without the tail and its structure was determined using nuclear magnetic resonance 
spectroscopy (Pugh et al. 2006). 
 
Ubiquitination could be critical as the 3-end processing complex proceeds through a cycle of 
assembly, cleavage, poly(A) addition, and release from the mature mRNA. Otherwise, 
ubiquitin-mediated degradation could reduce the level of an inhibitor of processing or help 
maintain appropriate stoichiometry of the subunits that make up the processing complex. 
When ubistatin A (an inhibitor that binds near the hydrophobic patch on the surface of 
ubiquitin) interacts with ubiquitin-binding domains (UBDs) in an in vitro process, it blocks 
the interaction of ubiquitinated proteins with other proteins. The poly(A) addition, 3’ -end 
processing and mRNA splicing in vitro was inhibited however, specific to protein having 
longer U-rich tracts flanking the cleavage site, RNA containing the CYC1 poly(A) site not the 
UA-rich efficiency element RNA containing the GAL7 site. When the proteasomal inhibitor 
MG132 was added in processing in vitro, it affected poly-adenylation suggesting that active 
protein degradation contributes directly to efficient processing in vitro (Lee and Moore 
2014). 
 
1.3 The role of RBBP6 in ubiquitination 
1.3.1 The ubiquitin proteasome system 
Ubiquitination is a post-translation modification that is involved in the control of activity and 
function of cellular proteins. It is one of the most important post-translation modifications, 
affecting the fate of proteins with a variety of outcomes, including proteasomal 
degradation, endosomal sorting, endocytosis, and DNA repair. The 8.5 kDa ubiquitin moiety 
is transferred to the target protein where it affects the target protein structure, activity, 
stability, localization, or interaction. Hence, ubiquitination orchestrates the regulation of a 
number of cellular processes such as membrane trafficking, signal transduction, cell division, 
apoptosis, and immune response (Wilkinson et al. 2005; Kulathu and Komander 2012).  
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Ubiquitination occurs when an ubiquitin moiety is covalently attached primarily to lysine 
residues, but less commonly to cysteine, threonine, or tyrosine residues, of the target 
protein (McDowell and Philpott 2013). Proteins are conjugated with ubiquitin via sequential 
action of enzymatic cascade involving E1, E2 and E3 enzymes. The ubiquitin-activating E1 
activates ubiquitin through the formation of a high-energy thioester bond between the 
ubiquitin C-terminal glycine and the active cysteine in the E1, in the presence of adenosine 
triphosphate (ATP). Once activated, ubiquitin is transferred from the cysteine residue of E1 
to a cysteine on the ubiquitin-conjugating E2 enzyme. Finally, the ubiquitin-conjugating E3 
ligase forms a complex with the E2 conjugating enzyme to facilitate the transfer of ubiquitin 
to a lysine on the target protein where an isopeptide bond is formed between the backbone 
carboxyl group of the glycine and the side-chain amino group of the lysine (see Figure 1.2) 
(Pickart and Eddins 2004; Dye and Schulman 2007).  
 
There are two isoforms activating E1 enzymes in human cells, and there are about 40 
conjugating E2 enzymes. Moreover, there are thousands of ubiquitin E3 ligases because 
they are specific for the target substrate and there are many different proteins to be 
ubiquitinated (Semple et al. 2003). There are two classes of ubiquitin E3 ligase, those 
containing the homologous to E6-AP C-terminus (HECT) domain and those containing the 
really interesting new gene (RING) or the U-box domain (Deshaies and Joazeiro 2009). With 
HECT E3s become covalently attached to the Ub before being transferred to the substrate. 
Catalytic cysteine forms a thioester linkage with the C-terminus of Ub, identical to the E2-Ub 
linkage. The RING/U-box E3s, the RING finger is characterised by the presence of two zinc 
ions with a conserved pattern of eight cysteine or histidine residues in a “cross-braced” 
structure and U-boxes have identical structures, but do not bind any zinc ions and do not 
have the conserved Cys/His residues. In contrast to the HECT E3s, the RING-containing 
ligases facilitate the transfer of ubiquitin from the E2 to the substrate without any direct 
contact with ubiquitin (see Figure 1.2) (Dye and Schulman 2007, Metzger et al. 2014).  
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Figure 1.2: Schematic representation of ubiquitination mechanism. A cascade of enzymes is 
required to ubiquitinate substrate via sequential action. These enzymes include the activating E1 
enzyme, conjugating E2 enzyme and E3 ligase. The two classes of E3 ligase, the RING and HECT are 
represented. HECT E3 ligases, directly contact ubiquitin before it is transferred to the substrate, 
while RING E3 ligases directly transfer ubiquitin to substrate, without any contact with ubiquitin 
molecule (Woelk et al. 2007).  
 
1.3.2 Classification of the RING domain 
RING-type or U-box domains are found in many different structural contexts. While many 
exist as monomers, a notable feature of RING-type or U-box E3s is their tendency to form 
homo-dimers and hetero-dimers. Dimerisation is of physiological significance because 
mutations on amino acids that disrupt dimer formation abolish E3 ligase activity. Although 
homo-dimer formation is common, many RING domains including cIAP, RNF4, BIRC7, 
Ring1b,etc, can also form hetero-dimers, in some cases preferentially, with an inactive RING 
partner such as BRCA1-BARD1, MDM2-MDMX (or HDMX/HDM4 in human), and RING1B–
Bmi1 (Metzger et al. 2014). The inability of mutated RING fingers to promote ubiquitin 
transfer suggests that dimerisation of RING finger is vital to enhance the local concentration 
of E2 enzymes and to promote catalytic processing (Yin et al. 2009, Liew et al 2010). 
 
The cysteine-rich region of RBBP6 between residues 249-335 has been classified as both the 
RING finger and the U-box, due to eight conserved cysteine and the two bound zinc ions and 
conserved pattern of hydrophobic residues, respectively (Aravind and Koonin 2000). The U-
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boxes are considered the hallmark of E4 ligase, which facilitates the formation of ubiquitin 
chain during ubiquitination (Cyr et al. 2002). This nature stabilizes the structure of protein, 
for example, the presence of the zinc ion increases thermal and conformational stability of 
domains. Additionally, some RING fingers have been shown to be a homo-dimer, for 
example, MDM2 RING finger, and this nature has been shown to be pivotal in ubiquitination 
(Nikolay et al. 2004). Like the MDM2 RING finger, the structure of the RING finger from 
RBBP6 has previously been solved using Nuclear Magnetic Resonance spectroscopy (NMR) 
and shown to homo-dimerize along the same interface found in many RING fingers (see 
Figure 1.3).  
 
 
Figure 1.3: Cartoon secondary structure of the RBBP6 RING finger homo-dimer. Subunits of RBBP6 
RING finger are shown in red and green, stabilized by the zinc ions in yellow spheres (Kappo et al. 
2012).  
 
RING fingers can be classified according to coordination of the zinc ion by cysteine (C) and 
histidine (H) residues; C3HC4 being the most common classification, although some 
classification such as C3HHC3 exist (Stone et al. 2005). Kappo and colleagues have shown 
that RBBP6 RING finger consists of eight conserved cysteine residues that coordinate the 
two zinc ions in a cross-braced fashion. This means that one of the zinc ions is coordinated 
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by the first and third cysteine residues and the other ion by the second and fourth cysteine 
residues. The Cys259, Cys262, Cys280, and Cys283 are clustered and oriented to coordinate one 
Zn2+ ion. Similarly, Cys274, Cys275, Cys296, and Cys299 are in proximity for another Zn2+ ion (see 
Figure 1.4). As the result, the RBBP6 RING is classified as C4C4 RING finger (Kappo et al. 
2012). 
 
 
Figure 1.4: Cysteine residues involved in coordination of zinc ions in the RBBP6 RING finger. (A) 
Schematic representation of the RING finger domain indicating the ‘cross-brace’ topology for zinc ion 
coordination. (B) The sequence of the RING finger showing cysteine residues in orange and the 
residues, asparagine (N312) and lysine (K313) forming part of the homo-dimerization interface of the 
homo-dimer.  
 
Dimerisation and oligomerisation can confer several different structural and functional 
advantages to proteins, including improved stability and activity. However, unwanted 
oligomerisations of proteins also lead to the formation of pathogenic structures 
(Marianayagam et al. 2004). The homo-dimeric RING E3s both RINGs have the intrinsic 
capacity to interact functionally with E2s, however, this appears not to be the case for some 
hetero-dimeric RINGs. MDM2 can homo-dimerize and is active, MDMX has little tendency to 
form a homo-dimer and it does not possess E3 ligase catalytic activity. However, the hetero-
dimer formation of the RING domains of both MDM2 and MDMX is critical to retain the 
level of p53. The hetero-dimer formation of MDM2 and MDMX is important, as it enhances 
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the stability and activation of MDM2 during the inhibitory process of p53 (Tanimura et al. 
1999; Okamoto et al. 2005; LeBron et al. 2006; Cheng et al. 2011). In BRCA1-BARD1, BRCA1 
functions with E2, while its partners BARD1 serve to enhance activity, potentially interact 
with substrates and stabilize the complex (Hashizume et al. 2001). 
 
1.3.3 Functional processes of ubiquitination 
There are different ways in which post-translational modification by ubiquitin occurs. In 
mono-ubiquitination a single ubiquitin moiety attaches to a lysine residue of the target 
protein and orchestrates endocytosis, endosomal sorting, histone regulation, and DNA 
repair, virus budding and nuclear export. Multiple mono-ubiquitination is the transfer of a 
single ubiquitin moiety to several lysine residues of the target protein; this modification is 
involved in receptor internalization and endocytosis (Garcin et al. 2002, Oqawa et al. 2005, 
Gatza et al. 2007). Poly-ubiquitination occurs when a lysine residue on ubiquitin itself serves 
as acceptor of another ubiquitin moiety, thus forming a chain of ubiquitins. In many cases, it 
has been found that the same internal lysine is used predominantly in a poly-ubiquitin 
chain, allowing them to be classified as lysine48-linked chains or lysine63-linked chains. A 
chain of four or more ubiquitin monomers attached by linkages involving lysine48 (a so-
called lysine48-linked poly-ubiquitin chain) promotes recruitment of the substrate to the 
26S proteasome and its subsequent degradation. Lysine63-linked poly-ubiquitin chains can 
act as a signal for DNA repair, activation of transcription factors, endocytosis and activation 
of protein kinases (Hicke 2001; Weissman 2001; Hoppe 2005, Nathan et al. 2013).  
 
The proteasome system orchestrates the quality of protein by degradation of damaged or 
mis-folded proteins (Brodsky and McCracken 1999; Davies 2001; Goldberg 2003). Proteins 
tagged with lysine48-linked poly-ubiquitin chain are degraded by the 26S proteasome in the 
presence of ATP, which degrades cytosolic proteins in eukaryotes (Chandu and Nandi 2004). 
The 26S proteasome consists of the 20S proteasome, which harbours the proteolytic site, 
and two 19S regulators. The 20S takes the form of a barrel made up of four rings of seven 
subunits each. The subunits fall into two types, α and β, giving a α7β7β7α7 configuration. The 
proteolytic active sites are located on β-subunits 1, 2 and 5, which have chymotryptic 
(cleaves after hydrophobic side-chains), tryptic (cleaves after positively charged side chains) 
and post-glutamyl (cleaves after negatively charged side-chains) respectively. Among the 
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three types of activity, the proteasome is capable of cleaving any polypeptide chain into 
very small peptides. The 19S regulator takes the form of a cap, which fits on one or both 
ends of the 20S subunit and regulates access in an ATP-dependent manner. The base of the 
19S particle takes the form of a seven-fold ring of subunits with ATPase activity (see Figure 
1.5) (Pickart and Cohen 2004; Nandi et al. 2006). Although the details are still to be worked 
out, it seems that, an interface on the 19S recognises and binds to lysine48-linked poly-
ubiquitin chains, facilitating recruitment and unfolding of substrate proteins, resulting in the 
substrate being fed into the 20S barrel and degraded (Thrower et al. 2000, Belzile et al. 2010). 
 
 
Figure 1.5: The formation of a 2000 kDa 26S proteasome. This system is formed by combination 700 
kDa 20S proteasome and 19S regulator in the presence of ATP (Nandi et al. 2006).  
 
MG132 (carbobenzoxy-Leu-Leu-leucinal) is a peptide aldehyde, which effectively inhibits the 
proteolytic activity of the proteasome. Han and colleagues showed that MG132 inhibits the 
growth of HeLa cells via inducing the cell cycle arrest as well as triggering apoptosis (Han et 
al. 2009). Protein ubiquitination and degradation are used in anti-cancer therapy, for 
example, Hsp90 inhibitor is used as anti-tumours agents, which prevent or inhibit the 
formation or growth of tumours. This small inhibitor affects the ubiquitination and 
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degradation of receptor and non-receptor kinases, including Erb-B2, epidermal growth 
factor receptor, and Src family kinases (Messaoudi et al. 2008). 
 
RBBP6 is a RING finger-containing protein. As discussed earlier, RING fingers are closely 
associated with E3 ubiquitin-ligases, where their function is to recruit the ubiquitin-bound 
E2. E3s typically also contain a substrate-binding domain, which simultaneously recruits the 
substrate, leading to transfer of ubiquitin from the E2 to the substrate. For example, C-
terminus of Hsp70 (CHIP) has a TPR-repeat domain at the N-terminus, which recruits 
substrates (Ballinger et al. 1999). Many E3 ligases have been shown to be able to 
ubiquitinate themselves (a process known as auto-ubiquitination). In many cases, this is 
likely to play a role in auto-regulation of the E3; however, auto-ubiquitination activity is 
often used as a proxy for substrate ubiquitination activity, especially in in vitro studies, 
where the absence of a separate substrate greatly simplifies the assay. The BCA2 protein, a 
RING-type E3 ubiquitin ligase is over-expressed in more than 50% of invasive breast cancers 
compared with normal tissues. It increases the proliferation of NIH3T3 fibroblasts, whereas 
siRNA inhibits the growth of BCA2-expressing. In addition, it is able to ubiquitinate itself 
dependent on its RING domain. BCA2 auto-ubiquitination activity correlates with its 
stability. When mutations of both the BZF domain cysteines and COOH-terminal lysines 
(K232R/K260R) located within and nearby the RING domain resulted in decreased amounts 
of BCA2 protein relative to wild-type protein in HEK293T cells. BCA2 RING is also required 
for BCA2 auto-ubiquitination and poly-ubiquitination is likely to be dependent on the two 
NH2- terminal lysines (Amemiya et al. 2008). 
 
RBBP6 plays a role in ubiquitination of Y-Box Binding Protein 1 (YB-1) and zBTN38 (Chibi et 
al. 2008, Miotto et al. 2014). Y-box binding protein (YB-1) contains a “cold shock” domain 
(CSD) conserved in nucleic acid-binding proteins. It is a transcription factor and a 
translational regulator (Kohno et al. 2003). YB-1 has been described as an mRNA chaperone. 
YB-1 is also a cellular stress response factor that prevents the early onset of senescence in 
cultured cells in vitro. This was suggested after the requirements of YB-1 for the normal late 
embryonic development and survival of mice. YB-1 was reported to be ubiquitinated by the 
Skp-1/Cul1/F-Box (SCF) E3-ubiquitin ligase complex. F-Box protein, FBX33 belongs to an SCF 
E3-ubiquitin ligase that targets YB-1 for ubiquitination and degradation by the proteasome. 
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FBX33 is part of a SCF complex demonstrated after immunoprecipitated complexes revealed 
that FBX33 co-precipitated conserved SCF components Skp1, Cul1, and Rbx/Roc1. Hence, 
FBX33 binds to the CSD of YB1 and recruits the Skp-1/Cul1 to YB-1 (Lutz et al. 2006) 
 
Using a yeast 2-hybrid assay with the RING finger from RBBP6 as bait, Chibi and co-workers 
identified the C-terminal 62 amino acids of YB-1 as an interaction partner of RBBP6 (Chibi et 
al. 2008). Overexpression of the RING finger in mammalian cells led to dose-dependent 
suppression of cellular YB-1 in a proteasome-dependent manner, suggesting that YB-1 was 
being ubiquitinated by RBBP6, leading to its destruction in the proteasome. In the same 
study the RING finger was shown to interact with the transcriptional repressor protein 
zBTB38 (Chibi et a 2008). In a subsequent study, RBBP6 was shown to ubiquitinate and 
destabilize zBTB38 protein, and to prevent DNA damage (Miotto et al. 2014). Knockdown of 
RBBP6 led to a decrease in ubiquitinated zBTB38 in cells and over-expression of RBBP6 to an 
increase in ubiquitinated zBTB38. Knockdown of RBBP6 represses MCM10 at the protein 
and mRNA levels and MCM10 is re-expressed in response to the knockdown of zBTB38. 
MCM10 is required for DNA replication in eukaryotes. RBBP6/zBTB38/MCM10 is critical for 
genome stability in mammalian cells (Miotto et al. 2014). 
 
1.4 The role of RBBP6 in cancer  
Cancer is an abnormal growth of cells caused by disregulation of cell proliferation and cell 
death. Ultimately, this can evolve into a population of cells that can invade tissues and 
metastasize to distant sites causing significant morbidity and, if untreated, mortality of the 
host. Researchers have demonstrated that over-expression of receptors and growth factors, 
oncogene activations, and inactivation of tumor suppressor genes are the source causes for 
the development of an aggressive and resistant cancer phenotype (Aggarwal et al. 2014). 
The architecture of tissues is highly regulated and there is extensive intracellular 
communication conducted primarily by mitogens and communicated into the cell by trans-
membrane signalling pathways (Dhillon et al. 2007). For example, the p53 pathway 
responds to stresses that can disrupt the fidelity of DNA replication and cell division. A stress 
signal is transmitted to the p53 by post-translational modifications, which activate p53 as a 
transcription factor that initiates a program of cell cycle arrest, cellular senescence, or 
apoptosis. The transcriptional network of p53-responsive genes produces proteins that 
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interact with a large number of other signal transduction pathways in the cell and a number 
of positive and negative auto-regulatory feedback loops act upon the p53 response 
(Vogelstein et al. 2000, Lowe and Sherr 2003, Harris and Levine 2005). 
 
A number of studies have found that RBBP6 is up-regulated in cancers. RBBP6 was found to 
be an independent prognostic factor for stem cells in gastric cancer. RBBP6 was one of eight 
genes found to be up-regulated in the side population (SP) cells, a sub-population of gastric 
cancer cells, which serve as a model for stem cells, relative to its levels in respective parent 
cell lines. Knockdown of RBBP6 with siRNA led to a significant decrease in the invasion and 
migration activity of SP cells, which established RBBP6 as a major marker for metastasis in 
gastric cancer (Morisaki et al. 2014). 
 
In subsequent investigations, RBBP6 was found to significantly correlate with tumour 
progression in oesophageal cancer and cervical cancer. Up-regulation of RBBP6 was found in 
oesophageal cancer cells, whereby it correlates with poor clinical progression of 
oesophageal cancer (Yoshitake et al. 2004). The level of p53 in normal unstressed cells is low 
due to proteasomal degradation promoted by E3 ligase activity. In stressed cells, the level of 
p53 is in abundance, due to disruption of its degradation. In colon cancer, up-regulation of 
RBBP6 by mutant TP53 protein has been associated with a poor survival rate (Chen et al. 
2013). The knockdown of RBBP6 with siRNA led to p53 gene expression involved in cell 
death pathways and apoptosis, hence, reduction of cell growth compared to the control 
sample. Silencing RBBP6 may therefore be a novel strategy to promote camptothecin-
induced apoptosis in breast cancer cell (Moela et al. 2014). In conclusion, RBBP6 is a 
promising prognostic biomarker and a therapeutic target for variety of cancer.  
 
1.5 Possible models for involvement of RBBP6 in regulation of p53  
Studies of p53 functions have revealed that its regulation is crucial in understanding the 
defence mechanisms against cancer. It functions as a transcription factor for a number of 
genes - critical for cell cycle arrest, apoptosis, and senescence, and exhibit DNA binding 
activity. p53 is found to be deleted, mutated, or mis-regulated in the majority of cancers 
(Hainaut et al. 1997; Levine 1997). In normal unstressed cells, p53 is unstable and present at 
low levels to allow normal growth. Its levels increase rapidly in response to a variety of 
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genotoxic stresses, including X-rays, ultraviolet (UV) radiation and certain chemotherapeutic 
agents that damage DNA. Up-regulation of p53 induces the expression of a cohort of genes, 
including MDM2, cyclin G, GADD45, WAF1/p21/CIP1 and Bax, each regulating different 
aspects of cell growth arrest and apoptosis (Gottlieb and Oren 1998). 
 
MDM2 is a transcriptional target of p53, creating a p53-MDM2 negative feedback loop 
which keeps cellular levels of both proteins low (Li et al. 2003, Hunziker et al. 2010). In 
contrast, in human cancer cells that carry mutant p53 alleles, there is excess p53 
concentration. When mutated p53 loses its power as a transcription factor, it is unable to 
induce MDM2, through which it escapes the degradation process. Thus, human cancer cells 
often contain high concentrations of non-functional p53. MDM2 binding to p53 conceals its 
transactivation domain, thereby inhibiting p53-dependent effects on cell cycle inhibition 
and apoptosis (Barak et al. 1993, Harms and Chen 2006). 
 
The tumour suppressor protein p53 induces the expression of a cohort of genes - MDM2, 
cyclin G, GADD45, WAF1/p21/CIP1 and Bax - critical for cell cycle arrest and apoptosis in 
response to stress to maintain the integrity of the genome through transcription-dependent 
and –independent mechanisms. RBBP6 interacts with p53 whereby it suppresses the binding 
of p53 to DNA (Simons et al. 1997). RBBP6 also cooperates with MDM2 (denoted as HDM2 
in human) in ubiquitinating p53 leading to proteasomal degradation of p53 (Li et al. 2007).  
 
Alternatively, it could be that RBBP6 is acting as an E4 ligase to activate the poly-
ubiquitination activity of MDM2, which on its own is only able to catalyse mono-
ubiquitinates of p53. Otherwise, it could be that RBBP6 is hetero-dimerizing with MDM2 to 
poly-ubiquitinate p53. To answer that question we would have to determine whether the 
RING fingers of RBBP6 and MDM2 interact. RBBP6 possibly displaces MDMX from 
MDM2/MDMX. Alternatively, does RBBP6 suppress itself by auto-ubiquitinating itself? To 
answer that question we would have to measure the auto-ubiquitination of RBBP6, which 
has never been done.  
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1.6 Questions to be addressed in the thesis  
Retinoblastoma Binding Protein 6 (RBBP6) is a RING finger-containing protein that plays a 
role in 3’-end poly-adenylation of mRNA transcripts as well as acting as an E3 ubiquitin 
ligase against a number of proteins involved in tumourigenesis, including p53. Many E3 
ubiquitin ligases form homo-dimers and dimerisation is important for their activity; 
structural studies of the isolated RING finger of RBBP6 showed that it forms a weak homo-
dimer (Kappo et al. 2006). Auto-ubiquitination of an isolated RING finger in vitro has been 
reported previously (Everett et al. 2010). As a means of understanding the structural 
functions of RBBP6, a number of questions need to be answered: do larger fragments of 
RBBP6 form stronger homo-dimers than the isolated RING finger and, if so, how strong is 
the dimerisation, and which residues are involved in the dimerisation? Does the DWNN 
domain contribute to the dimer interface? Does RBBP6 auto-ubiquitinate itself, and does 
this catalyse degradation in the proteasome that may explain the low levels of RBBP6 found 
in most cells? Does RBBP6 interact directly with MDM2 and, if so, where is the interface? Do 
they possibly form hetero-dimers through their RING finger domains like those of MDM2 
and MDMX? 
 
This thesis aims to address three of these questions: (1) Can we identify a larger N-terminal 
fragment of RBBP6 which forms a stronger homo-dimer than the isolated RING finger (2) 
can RBBP6 auto-ubiquitinate itself and, if so, is dimerisation crucial for this activity, and (3) 
does the RING finger domain of RBBP6 interact with the RING finger of MDM2? 
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Chapter 2: Materials and Methods 
 
2.1 Materials and suppliers 
40 % 37.5:1 Acrylamide: bis-acrylamide    Promega 
Acetone  Merck 
Agarose  Sigma 
Ammonium persulphate Merck 
Ampicillin     Sigma 
Antibodies Santa Cruz Biotechnology 
Bovine serum albumin Roche 
Bromophenol Blue   Merck 
Casein Sigma 
Clarity™ Western ECL substrate BioRAD 
DNAse I                                                                                              Sigma 
EDTA-free protease inhibitor cocktail Roche 
Ethanol Merck 
Ethylene Diamine Tetra Acetic Acid (EDTA) Merck 
GeneJet Gel Purification kit ThermoFisher Scientific 
GenElute HP Plasmid Miniprep Kit  Sigma 
Glacial acetic acid                                                                               Merck 
Glycerol                                                                                               Merck 
Glycine Merck 
Glutathione agarose Sigma 
Hydrochloric acid (HCl) Merck 
Imidazole   Sigma 
Isopropanol      Merck 
Isopropylβ-D-1-thiogalactopyranoside (IPTG) Sigma 
Kanamycin sulphate Sigma 
Lysozyme Roche 
Luria Bertani broth Merck 
Magnesium chloride                                                                            Merck 
Methanol Merck 
 
 
 
 
  
17 
 
N, N, N’, N’-Tetra methylethylene-diamine (TEMED)                      Sigma 
Nutrient agar                                                                                        Merck 
Potassium Acetate Merck 
Potassium Chloride Merck 
Protein molecular weight standard Fermentas 
EDTA-free protease inhibitor cocktail Roche 
ATP magnesium salt (Mg.ATP) Sigma 
Monopotassium phosphate Merck 
Reduced glutathione (GSH) Sigma 
Restriction enzymes Fermentas 
RNAse A                                                                                              Roche 
Sodium azide Merck 
Sodium chloride Merck 
Sodium phosphate Merck 
T4 ligase Fermentas 
Tris(hydroxymethyl)-amino-methane Merck 
Triton X-100 Merck 
Tryptone Merck 
Tween-20 Merck 
Nickel sepharose Amersham Biosciences 
Zinc sulphate Merck 
 
2.2 General stock solutions, buffers, and media 
10x Phosphate buffered saline (PBS):  
1.36 M NaCl, 0.027 M KCl, 0.1 M Na2HPO4-7H2O, 0.18 M KH2PO4, adjusted to pH 7.4 with 
HCl. 
10x SDS electrophoresis buffer: 
25 mM Tris, 0.1 % (m/v) SDS and 250 mM Glycine. 
10x TBE (Tris/Borate/EDTA):  
0.9 M Tris (pH 8.3), 0.89 M boric acid and 25 mM EDTA, stored at room temperature and 
diluted ten-fold for electrophoresis agarose gels. 
2x SDS-PAGE Gel Sample Buffer:  
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20 % (w/v) SDS, 1.5 M Tris (pH 6.8), 15 % (v/v) glycerol and 1.8 % (w/v) bromophenol blue, 
store at room temperature. In addition, 10 % (v/v) β-mercaptoethanol was added to the 
buffer immediately prior to use and stored at -20 °C. 
50x Tris-acetate (TAE) DNA Electrophoresis Buffer:  
2 M Tris-HCl, 1 M acetic acid and 0.05 M EDTA in dH2O, and stored at room temperature. 
Ammonium persulfate:  
10 % (w/v) APS in dH2O, and stored at -20 °C. 
Ampicillin:  
100 mg/ml in deionised water, filter-sterilised and stored at -20 °C. 
Binding Buffer (Protein purification): 
1x PBS, 5 % (v/v) glycerol, and 1 mM DTT. 
Chloramphenicol: 
34 mg/ml solution in ethanol, filter-sterilised and stored at -20 °C. 
Cleavage buffer: 
50 mM Tris, pH 8.0, 20 mM NaCl, and 1 mM DTT. 
Coomasie Blue Staining Solution:  
0.25 % (w/v) Bromophenol Blue, 40 % (v/v) ethanol, and 10 % (v/v) acetic acid in dH2O. 
Destaining solution: 
40 % (v/v) ethanol, 10 % (v/v) acetic acid made up with dH2O. 
Dithiothreitol (DTT): 
1 M DTT in 10 mM sodium acetate (pH 5.2), filter-sterilised and stored at -20 °C. 
Isopropyl β-D-1-thiogalactopyranosid (IPTG):  
1 M IPTG in deionised water, filter-sterilised and stored at -20 °C. 
Kanamycin: 
30 mg/ml in distilled water, filter-sterilised and stored at -20 °C. 
Luria Bertani Agar: 
10 g/l tryptone, 5 g/l yeast extract, 5 g/l sodium chloride and 10 g/l agar in dH2O. 
Luria Bertani Broth:  
10 g/l tryptone, 5 g/l yeast extract, and 5 g/l sodium chloride in dH2O. 
Lysis Buffer:  
50 mM Tris, pH 8.0, 150 mM NaCl, 0.5 % (v/v) Triton X-100, 5 % (v/v) glycerol, 1 mM DTT,  
100 µM ZnSO4, CompleteTM EDTA-free protease inhibitor cocktail, 50 μg/ml DNAse and 100  
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μg/ml lysozyme. 
Mg.ATP: 
0.1 M Mg.ATP in dH2O. 
Nutrient agar:  
31 g/l nutrient agar in distilled water. 
PBS-T (Phosphate buffered saline-Tween-20): 
1x PBS containing 0.1 % (v/v) Tween 20. 
Separating Buffer:  
1.5 M Tris-HCl, adjusted to pH 8.8 with HCl.  
Sodium acetate:  
2 M sodium acetate in deionised water, adjusted to pH 5.2 with diluted acetic acid. 
Stacking Buffer: 
0.5 M Tris-HCl, adjusted to pH 6.8 with HCl.  
Transformation buffer 1 (Tfb1) buffer:  
30 mM Potassium acetate, 50 mM MnCl2, 0.1 M KCl, 10mM CaCl2 and 15 % (v/v) glycerol. 
Transformation buffer 2 (Tfb2) buffer:  
9 mM MOPS, 50 mM CaCl2, 10 mM KCl and 15 % (v/v) glycerol. 
Transfer Buffer:  
25.9 M Glycine, 20.9 M Tris, and 779.9 M SDS in 20 % (v/v) ethanol and stored at -20 °C. 
Tris-HCl Buffer:  
1 M Tris-HCl, adjusted to pH 8.0 with HCl. 
TYM:  
20 % Tryptone, 0.5 % Yeast Extract, 0.1 M NaCl, 0.2 % (w/v) glucose, and 10 mM MgCl2. 
Wash Buffer: 
1x PBS and 1 mM DTT. 
Zinc Sulphate:  
0.1 M ZnSO4 in dH2O. 
 
2.3 Antibodies used for immunoblotting 
Anti-RBBP6-RING: rabbit polyclonal raised in the laboratory of Prof Dirk Bellstedt, 
Department of Biochemistry, University of Stellenbosch, against a recombinant fragment 
corresponding to residues 249-335 of full-length human RBBP6.  
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Ubiquitin antibody: rabbit polyclonal IgG with epitope corresponding to amino acid residues 
1-76 representing full-length ubiquitin of human origin, Santa Cruz Biotechnology Inc (Santa 
Cruz, CA, USA); product code sc-9133 
 
2.4. Expression plasmids 
2.4.1 pGEX-6P-2 
The pGEX vector was developed employing a gene encoding Glutathione S-transferase (GST) 
from the parasitic helminth Schistosoma japonicum (Smith and Johnson 1988). The 26 kDa 
GST moiety binds with high affinity to glutathione coupled to a Sepharose matrix. GST fusion 
protein can be applied in the study of protein-protein interactions via GST pull down assays 
(Singh and Asano, 2007). 
 
The pGEX-6P-2 vector (GE Healthcare Life Sciences, Chalfont St Giles, UK) (see Figure 2.1 
panel A) allows bacterial expression of target proteins attached to the C-terminus of the 26 
kDa glutathione-S-transferase protein from Schistosoma japonicum. Expression is driven by 
a tac promoter which is induced by the synthetic lactose analogue Isopropyl β-D-1-
thiogalactopyranoside (IPTG). It contains a multiple cloning site (MCS) (see Figure 2.1 panel 
B), to facilitate the un-directional cloning of DNA inserts. The 3C protease site - Leu-Glu-Val-
Leu-Phe-Gln-Gly-Pro - between the GST-tag and the MCS allows the removal of GST from 
the fusion protein following expression. Removal of the GST tag leaves a residual five-
residue sequence Gly-Pro-Leu-Gly-Ser attached to the N-terminus of the protein. The vector 
incorporates an ampicillin resistant gene, to allow bacterial resistance to the antibiotic 
(ampicillin) 
 
2.4.2 pET-28a 
Members of the pET family of expression vectors (Merck KGaA, Darmstadt, Germany) use a 
T7 promoter to reduce leaky expression in Escherichia coli (E. Coli) expression hosts since it 
is not recognised by host RNA polymerases. T7-specific polymerases are supplied from a T7 
RNA polymerase gene incorporated into the chromosome of DE3 expression hosts, under 
control of a lac promoter. Addition of IPTG induces expression of the T7 RNA polymerase, 
which in turn, induces expression of the target gene. The pET-28a vector allows for the 
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optional addition of either N- or C-terminal 6His tags, dependent on the sites of 
incorporation of the target gene, as can be seen from the multiple cloning cassettes shown 
in Figure 2.2. The vector incorporates a kanamycin resistance gene to allow selection with 
kanamycin. 
 
 
 
 
 
Figure 2.1: Restriction map and main features of the pGEX-6P-2 vector. (A) The pGEX-6p-2 vector is 
a 4985 bp C-terminal GST expression vector with a tac promoter, allowing induction of expression of 
the target protein using IPTG. (B) The multiple cloning site (MCS), into which the target cDNA is 
inserted, immediately following the 3C protease site. Proteolytic cleavage of the fusion protein takes 
place as indicated by the small arrow, leaving a number of residues attached to the beginning of the 
target protein. Figure generated using SnapGene Viewer snapgene.com. 
 
 
 
 
 
 
A 
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Figure 2.2: Restriction map and main features of the pET-28a vector. (A) The pET-28a vector is a 
5369 bp expression vector allowing for incorporation of both N-terminal and C-terminal 6His-tags. 
The recombinant protein is expressed under the control of a T7 promoter, which is induced 
indirectly by IPTG in DE3 expression hosts. (B) The multiple cloning site (MCS) allows for the optional 
addition of both N- and C-terminal 6His-tags, dependent on the sites of insertion of the target gene. 
Figure generated using SnapGene Viewer snapgene.com. 
A 
B 
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2.5 Bacterial culture 
2.5.1 Bacterial strains used 
Escherichia coli strain DH5α: F- endA1 glnV44 thi-1 recA1 relA1 gyrA96 deoR nupG 
Φ80dlacZΔM15 Δ(lacZYA-argF)U169, hsdR17(rK
- mK
+), λ–. This strain was used to produce 
plasmid DNA. 
Escherichia coli strain XL10-Gold: endA1 glnV44 recA1 thi-1 gyrA96 relA1 lac Hte Δ(mcrA)183 
Δ(mcrCB-hsdSMR-mrr)173 tetR F'[proAB lacIqZΔM15 Tn10(TetR Amy CmR)]. This strain was 
used to produce plasmid DNA. 
Escherichia coli strain BL21 (DE3) pLysS: F- ompT gal dcm lon hsdSB(rB
- mB
-) λ(DE3) 
pLysS(cmR). This strain was used to express recombinant proteins. Since it is a DE3 strain, it 
is suitable for use with pET expression vectors. 
Escherichia coli strain BL21-CodonPlus (DE3)-RIPL: B F– ompT hsdS(rB
-mB) dcm
+ Tetr gal 
λ(DE3) endA Hte [argUproLCamr] [argU ileY leuW Strep/Specr]. This strain was used to 
express recombinant proteins. Since it is a DE3 strain, it is suitable for use with pET 
expression vectors. It incorporates additional copies of tRNA genes corresponding to codons 
abundant in mammalian genes but rare in bacterial genes, increasing the efficiency of 
expression of mammalian genes in bacteria. 
 
2.5.2 Antibiotic selection 
E. coli cells were plated on nutrient agar containing either 100 µg/ml of ampicillin or 30 
µg/ml of kanamycin (Kan) depending on the resistance of the plasmid. The same 
concentration of antibiotics was used to maintain selection during bacterial growth in liquid 
culture. 
 
2.5.3 Preparation of competent Escherichia coli cells for transformation 
The desired strain of cells was streaked on a nutrient agar plate containing 10 mM MgSO4 
and incubated overnight at 37 °C. From the plate, a single colony was inoculated in a 20 ml 
of TYM broth, and incubated overnight at 37 °C with vigorous shaking. Then, 5 ml to 15 ml 
of the overnight culture was scaled up to 100 ml with TYM broth and incubated at 37 °C 
until the optical density at 550 nm (OD550) of 0.2 was reached. Thereafter, a 100 ml culture 
was diluted to 400 ml with fresh TYM broth and cells were grown at 37 °C until OD550 was 
between 0.4 and 0.6.  
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Subsequently, cells were rapidly chilled in ice water, with swirling, transferred into a 500 ml 
tube and bacterial culture was sedimented by centrifugation at 6000 rpm for 10 min, in a 
pre-cooled Beckman JA-10 rotor. The supernatant was discarded and the bacterial pellet 
was re-suspended in 50 to 250 ml ice cold transformation buffer 1 (Tfb1) and incubated on 
ice for 30 min. Cells were recovered by centrifuging at 6000 rpm for 10 min. The 
supernatant was discarded and a pellet was re-suspended in 30 ml ice-cold transformation 
buffer 2 (Tfb2). Subsequently, aliquots of 150 ml cells were prepared and directly incubated 
at - 80 °C. 
 
2.5.4 Transformation of plasmid DNA into competent Escherichia coli cells 
100 to 400 ng of plasmid DNA was added to pre-cooled 1.5 ml microfuge tube. Into the 
same tube, 50 µl of competent cells was added and mixed by gentle tapping and incubated 
on ice for 30 min. A control tube was set with competent cells but no plasmid DNA. Cells 
were transformed by heat shock at 42 °C for 45 seconds, and were then allowed to recover 
by incubating on ice for 5 min. Thereafter 500 µl of pre-warmed Luria Bertani broth (LB) was 
added and the bacterial culture was incubated at 37 °C in a shaking incubator for 60 min. 
Following incubation, 50 to 200 µl of transformed cells was plated on pre-warmed LB agar 
plates containing the appropriate antibiotic and incubated inverted for 16 hours at 37 °C. 
 
2.6 Preparation and manipulation of plasmid DNA 
2.6.1 Extraction of plasmid DNA 
A single colony of the transformed cells was inoculated in 20 ml of LB containing the 
appropriate antibiotic and incubated for 16 hours at 37 °C with vigorous shaking. The 
bacterial culture was sedimented by centrifugation at 43000 rpm for 10 min, in a pre-cooled 
Heraeus Megafuge 1.0R (ThermoFisher Scientific, Waltham MA, USA). Then, the 
supernatant was discarded. The plasmid DNA was extracted using the Wizard®Plus SV 
Miniprep Kit (Promega Corporation, Madison WI, USA) according to manufacturer’s 
instructions. The analysis of purity and quantification of the concentration of the plasmid 
DNA was determined using a NanoDrop ND-1000 Spectrophotometer (ThermoFisher 
Scientific, Waltham MA, USA).  
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2.6.2 Site directed mutagenesis 
In vitro site-directed mutagenesis was carried out using the QuikChangeTM Site Directed 
Mutagenesis Kit (Stratagene, San Diego CA, USA) according to the manufacturer’s 
instructions. Synthesized oligonucleotides incorporating desired mutation were mixed with 
components in the reaction mixture (See Table 2.1). Conditions for thermal cycling were as 
follows:  
 
Initial denaturation at 95 °C for 1 minute 
Denaturation at 95 °C for 30 seconds 
Annealing at 55 °C for 1 minute  
Extension at 68 °C for 10 minutes 
 
Table 2.1: PCR reaction mixture for site directed mutagenesis 
Components of reaction mixture Concentration/volume 
10x Reaction Buffer 1x 
dsDNA template 50 ng/µl 
Oligonucleotide primer forward 125 ng/µl 
Oligonucleotide primer reverse 125 ng/µl 
30 µl dNTP mix 1 µl 
2.5 U/µl Pfu TurboTM DNA polymerase 2.5 U 
Nuclease free H2O Add to final volume of 50 µl 
 
PCR reaction products were kept on ice for 2 min to lower the temperature below 37 °C. To 
ensure that sufficient amplification occurred, 10 µl of the reaction product was 
electrophoresis in 1x TAE buffer on a 1 % (w/v) agarose gel. Afterwards, 1 µl of Dpn I 
enzyme (10 U/µl) was added to the reaction products and mixed thoroughly by gently 
pipetting the solution up and down. The reaction mixture was spun down and incubated at 
37 °C for 1 hour to digest the non-mutated template DNA. The Dpn I-treated DNA was 
transformed into E.coli DH5α competent cells and the plasmid was isolated using GeneJet 
Plasmid Miniprep Kit (ThermoFisher Scientific, Waltham MA, USA) according to 
manufacturer’s instructions. The introduced mutation was confirmed by direct DNA 
sequencing. 
10 cycles 
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2.6.3 PCR amplification of target DNA 
Oligonucleotide primers were designed with different restriction enzyme sites. The forward 
primer incorporated the XhoI restriction site while the reverse primer incorporated the NcoI 
restriction site. The complementary restriction enzyme sites were in the pET-28a expression 
vector. The target DNA was successfully amplified using Dream Taq DNA Polymerase 
(ThermoFisher Scientific, Waltham MA, USA), according to manufacturer’s instructions. The 
PCR mixture, which consisted of components in Table 2.2, was mixed with oligonucleotide 
primers that incorporated the desired restriction site. In the final analysis, PCR amplified 
product was electrophoresis in 1x TAE buffer on 1 % (w/v) agarose gel. PCR thermal cycling 
conditions were as follows: 
 
Initial denaturation at 95 °C for 3 minutes 
Denaturation at 95° C for 30 seconds 
Annealing at 67 °C (Tm-5 °C) for 45 seconds  
Extension at 72 °C for 30 seconds 
Final extension at 72 °C for 10 minutes 
 
Table 2.2: PCR reaction mixture for amplifying target DNA 
Components of reaction mixture Concentration/volume 
10 X Dream Taq  Buffer 1 X 
dsDNA template 50 ng/µl 
Oligonucleotide primer forward 1 µM 
Oligonucleotide primer reverse 1 µM 
10 mM dNTP mix 0.2 mM 
5 U/µl Dream Taq DNA polymerase 1.5 U 
Nuclease free H2O Add to final volume of 50 µl 
 
2.6.4 Cloning of DNA fragment into the expression vector 
FastDigest enzymes (ThermoFisher Scientific, Waltham MA, USA) were used to digest the 
ends of the PCR amplicon and to open up the cloning vector, using the quantities set out in 
Table 2.3. Digested fragments were separated from contaminating enzymes and 
30 cycles 
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oligonucleotides on 1 % (w/v) agarose gels and the relevant bands excised using the GeneJet 
Gel Extraction kit (ThermoFisher Scientific, Waltham MA, USA)  
 
Table 2.3: Restriction enzyme digestion of vector DNA and DNA insert 
                   Concentration/Volume 
Components 
of reaction mixture 
Expression Vector PCR product 
10x FastDigest Buffer 1x 1x 
DNA 1 µg 0.2 µg 
20 µl FastDigest enzyme/s 1 µl 1 µl 
Nuclease free water Add to 20 µl Add to 30 µl 
 
The small size of the fragments released when the vector was doubly digested made it 
difficult to confirm that both enzymes were in fact digesting the vector efficiently. For that 
reason, single digests with both enzymes were also performed to act as positive controls for 
the enzymes.  
 
Digested PCR fragments were ligated into digested plasmid using the quantities set out in 
Table 2.4. The ligation reaction mixture was incubated at 22 °C for one hour using T4 DNA 
ligase, whereafter it was inactivated by incubating it at 70 °C for 5 min. 5 µl of the ligation 
reaction mixture was then transformed into competent E. coli XL10-Gold cells, as described 
in Section 2.5.4. The digested vector without the DNA insert was transfected in parallel to 
serve as a negative control. Cells from the experimental and the control transformations 
were plated out and grown overnight at 37 °C on agar containing 100 µg/ml antibiotics, as 
described in section 2.5.2. 
 
The following morning the numbers of colonies on the experimental (with insert) and the 
control (without insert) were counted and compared to determine whether there were 
significantly more on the experimental than the control plates. If there were, the cloning 
was deemed likely to have been successful. To confirm this conclusion, colonies from both 
experimental and control plates were picked using an autoclaved pipette tip and inoculated 
into 20 ml LB media containing the appropriate antibiotic and grown overnight at 37 °C. 
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Cells were sedimented by centrifuging using a Heraeus Megafuge 1.0R (ThermoFisher 
Scientific, Waltham MA, USA) for 15 min at 4300 rpm and plasmid DNA extracted using the 
GeneJet Plasmid Miniprep Kit (ThermoFisher Scientific, Waltham MA, USA). Double 
digestion using the restriction enzymes used in the cloning was carried out in order to 
release a fragment of the same size as the original PCR product. Positive clones were 
subjected to direct DNA sequencing; experimental sequence reads were compared against 
the expected sequences using the Blast2 server at the NCBI 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi). 
 
Table 2.4: Ligation reaction mixture of digested vector DNA and insert DNA 
Components of reaction mixture Concentration/Volume 
Vector DNA 50 ng 
Insert DNA 250 ng 
10x T4 DNA Ligase Buffer 2 µl 
T4 DNA Ligase 1 U 
Nuclease free water Add to 20 µl 
 
2.7 Expression and extraction of recombinant protein 
Single colonies of transformed E. coli cells were inoculated into 100 ml LB containing 100 
µg/ml ampicillin (Amp) or 30 µg/ml kanamycin (Kan) and 34 ug/ml chloramphenicol, 
followed by incubation at 37 °C with vigorous shaking overnight. The next morning the 100 
ml E. coli culture was scaled up to 1 L with 900 ml of LB containing the appropriate antibiotic 
and then incubated at 37 °C shaking until the optical density at 550 nm (OD550) was between 
0.4 and 0.6. Thereafter, protein expression was induced by the addition of IPTG to a final 
concentration between 0.5 - 1 mM and incubated overnight with shaking at a temperature 
between 25 °C and 30 °C. Cultures of RING finger-containing proteins were supplemented 
with 100 µM ZnSO4 to provide the necessary zinc ions. In the morning bacterial cells were 
sedimented by centrifugation in a pre-cooled centrifuge at 6000 g for 15 min. Pellets were 
then re-suspended in lysis buffer and stored at -20 °C until required for extraction of 
exogenous protein. 
 
 
 
 
 
  
29 
 
2.8 Protein Purification 
2.8.1 Cell lysis 
Cell pellets were thawed on ice after which cells were lysed by sonication, which comprised 
of 5 cycles: 30 seconds pulse, 30 seconds on ice. After sonication, cell lysate was centrifuged 
at 4 °C at 4300 rpm for 30 min to clear the lysate. The initial purification of the target 
protein out of cell lysate was carried out using self-poured gravity-flow columns containing 
glutathione-conjugated agarose (Sigma, St. Louis, MO, USA) in the case of GST-tagged 
proteins, or immobilised nickel sepharose (GE Healthcare Life Sciences, Chalfont St Giles, 
UK).  
 
Purification was carried out off-column so that the media could be periodically removed 
from the column, and thoroughly cleaned using 2 M NaCl, to enable it to be re-used multiple 
times. Columns were prepared by pouring 5 ml of the appropriate slurry into 20 ml 
disposable columns (BioRAD, Hercules CA, USA) and equilibrating with 5 column volume 
(CV) wash phosphate buffered saline. The clarified lysate was added into the column and 
the flow through was collected. The column was then washed with 3 CV of the Wash Buffer 
containing 40 mM imidazole in the case of the nickel sepharose column to reduce non-
specific binding. The protein of interest was then eluted from the column with Wash Buffer 
containing 20 mM reduced glutathione for glutathione agarose column or 500 mM 
imidazole for nickel sepharose column. Following elution columns were washed with 2 M 
NaCl containing 0.1 % of NaN3 and stored in 4 °C for re-use.  
 
2.8.2 Removal of GST 
Depending on the application, either GST was left attached to the target protein or 
proteolytically removed using 3C protease. The cleaved target protein was then separated 
from GST by a second round of glutathione affinity purification, following dialysis to remove 
free glutathione remaining from the first round of purification; the target protein was 
recovered in the flow through with the GST, un-cleaved GST-target, and GST-3C being 
retained by the column and subsequently eluted as described previously.  
 
In practice, the cleavage and removal of free glutathione were achieved successfully in one 
step. An un-cleaved fusion protein was transferred to SnakeSkin® Pleated Dialysis Tubing 
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(MWCO 3500 Da) (ThermoFisher Scientific, Waltham MA, USA), the bag was placed in 1 litre 
of Cleavage buffer and dialysed overnight at 4 °C with stirring.  
 
2.9 Size exclusion chromatography 
Residual GST and other contaminants were removed using size exclusion chromatography. 
The sample was concentrated into 5 ml and loaded onto a 120 ml Superdex 75 16/600 
column (GE Healthcare Life Sciences, Chalfont St Giles, UK), operated on an ÄKTA FPLC 
chromatography platform (GE Healthcare Life Sciences, Chalfont St Giles, UK). Eluting 
proteins were collected in 2 ml fractions using an automated fraction collector. The same 
column was used to estimate the molecular weight of proteins. Within a range of molecular 
weights of the proteins determined by the sizes of particles making up the matrix, a linear 
relationship is expected between the logarithm of the molecular weight (MW) and the 
elution volume (Ve). In the case of the Superdex 75 matrix, linearity is only expected over 
the range 10 – 75 kDa, as can be seen from Figure 2.3. This phenomenon can be used to give 
reasonably good estimates of the effective molecular weight of a protein complex by 
comparing it with a standard curve generated using proteins of known molecular weight. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3: Selectivity curves for Superdex SEC medium. The red solid line, which corresponds to 
Superdex 75, is roughly linear over the region 10000 – 75000 Da and can therefore be used to 
estimate effective molecular weights only over that range (GE Healthcare Life Sciences).  
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2.10 Preparation of self-cast gels for sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE)  
Purified fractions were analysed by SDS-PAGE using the BioRAD Mini-Protean system 
(BioRAD, Hercules CA, USA). Gels were self-poured using Laemmli’s method (Laemmli, 
1970), consisting of a 4 % (w/v) stacking gel on top of a 16 % (w/v) resolving. Exact 
quantities are set out in Table 2.5  
 
Table 2.5: Preparation of self-cast gels for SDS-PAGE 
Components 16 % Resolving gel 
solution 
4 % Stacking Gel 
solution 
Buffer 2.63 ml (1.5 M Tris-HCl) 1.25 ml (0.5 M Tris-HCl) 
40 % (v/v) acrylamide: bis-acrylamide 8 ml 0.5 ml 
10 % (w/v) SDS 105 µl 50 µl 
10 % (w/v) APS 50 µl 25 µl 
dH2O 3.2 ml 4 ml 
TEMED 10 µl 7.5 µl 
 
Proteins were prepared for SDS-PAGE by mixing 20 μl sample with equal volume of 2x SDS-
PAGE gel sample buffer, followed by incubation at 95 °C for 5 min. Samples were 
centrifuged for 2-5 min to pellet insoluble materials and then 10 µl to 15 µl were loaded into 
each well. Proteins were separated at a constant voltage of 150 V per gel. Following 
electrophoresis gels were removed from the plates and incubated in Coomassie Staining 
Solution for approximately 30 min with gentle rocking on an orbital shaker. Thereafter the 
gel was rinsed with water, and then incubated in a de-staining solution until the background 
was clear. 
 
2.11 In vitro auto-ubiquitination and proteasomal degradation of RBBP6-RING 
Bacterially expressed and purified E2, E1, and ubiquitin were kindly supplied by co-workers 
in the laboratory, Ms Lauren Jooste and Ms Tephney Hutchinson. Purified RBBP6-RING 
concentrations were estimated by measuring the absorbance at 280 nm using a NanoDrop 
ND-1000 Spectrophotometer (ThermoFisher Scientific, Waltham MA, USA) on the 
assumption that a concentration of 1 mg/ml has an absorbance of 1 unit. The final volume 
of the reaction was scaled up to 50 ml with PBS after the addition of the required 
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components for auto-ubiquitination. In addition to E1, E2 and ubiquitin, 4 mM Mg-ATP was 
added to the reaction mixture. The experimental reaction mixture consisted of all the 
components. After 2 hours 1 mM of purified proteasome (kindly purified from Hela cells by 
Ms Tephney Hutchinson) was added and samples were incubated overnight. 
 
2.12 In vitro GST pull down assays 
GST fusion proteins GST-RBBP6 and GST-MDM2 were expressed in bacteria and purified on 
glutathione sepharose to serve as bait. MDM2-6His was expressed in bacteria and purified 
on nickel column to serve as bait. GST was cleaved off fusion RBBP6 and purified to serve as 
prey. 0.5 mg/ml GST fusion protein, 0.12 mg/ml of prey and 20 μl glutathione agarose (20 % 
(m/v) slurry made using Binding Buffer) was incubated overnight mixing at 4 °C. The mixture 
was centrifuged at 1700 rpm for 2 min in a micro-centrifuge to pellet the beads and the 
supernatant was transferred into a fresh tube. The beads were then washed by re-
suspending in 1 ml 1x PBS containing 2 mM DTT, followed by centrifugation at 1700 rpm for 
2 min, this step was repeated five times. Finally, beads were re-suspended in 20 µl of 2x 
SDS-PAGE gel sample buffer. Samples were then boiled at 95 °C for 10 min, followed by 
centrifugation for 2 min. 12 µl of the sample was separated on SDS-PAGE and used for 
Western blot analysis. 
 
2.13 Immunodetection of proteins (Western blotting) 
Protein samples were separated using SDS-PAGE, as described in Section 2.8.5. A piece of 
0.2 μm, Immun-Blot® PVDF membrane (BioRAD, Hercules CA, USA) was cut to the same size 
as the gel and activated in 20 ml 2-propanol. Six pieces of MN218B blotting paper 
(Macherey Nagel, Düren, Germany) were cut to the same size. Both the membrane and the 
filter papers were equilibrated in Transfer Buffer and then assembled into the blotting 
cassette consisting of this order: three filter papers membrane, gel, and three filter papers. 
The cassette was loaded into the tray of the Trans-Blot® Turbo™Blotting System (BioRAD, 
Hercules CA, USA) and transfer performed for 20 min. Following the transfer, the membrane 
was blocked for 1 hour with 1 % (w/v) casein in PBS-T and then incubated for 1 hour with 
the appropriate primary antibodies. Following 3 x 10-min washes with PBS-T, the membrane 
was incubated with the appropriate HRP-conjugated secondary antibodies for 1 hour, 
followed by 3 x 10-min washes with PBS-T. The membrane was incubated with Clarity™ 
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Western ECL Substrate (BioRAD, Hercules CA, USA) before being visualised using a UVP 
BioSpectrum Imaging System (UVP, Upland, CA, USA). 
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Chapter 3: Results and Discussion 
 
3.1 Investigation of the oligomeric state of the R3 fragment of RBBP6 and putative 
monomerising mutants  
Retinoblastoma Binding Protein 6 (RBBP6) is a RING finger-containing E3 enzyme implicated 
in poly-ubiquitination of a number of cancer-associated proteins, including p53 (Li et al. 
2007, Chen et al. 2013). A number of E3s have been shown to form homo-dimers through 
their RING finger domains, and it has been suggested that dimerisation is required for 
ubiquitination activity (Tanimura et al. 1999; Okamoto et al. 2005; LeBron et al. 2006; Cheng 
et al. 2011). The structure of the RING finger from RBBP6 has previously been solved using 
Nuclear Magnetic Resonance spectroscopy (NMR) and shown to homo-dimerize along the 
same interface found in many RING fingers (Kappo et al. 2012).  
 
The dissociation constant, KD, of the interaction was determined in the same study and 
found to be in the order of 100 μM.This means that at concentrations above 100 μM it is 
expected to be predominantly homo-dimeric whereas at concentrations below 100 μM it is 
expected to be primarily monomeric. The same study identified two single amino acid 
substitutions - N312D and K313E – located within the dimerisation interface that are able to 
abolish the homo-dimerisation of the RING finger (Kappo et al. 201).  
 
A KD of 100 μM corresponds to a weak interaction that is unlikely to be biologically relevant 
since the concentration of RBBP6 is unlikely to reach 100 μM. The possibility exists, 
however, that, as is the case with other E3s, parts of RBBP6 outside of the RING may 
contribute to the dimerisation interface, in which case the KD of the complete molecule may 
be significantly less than 100 μM.  
 
Full-length RBBP6 is too large and poorly structured to be suitable for expression in bacteria. 
The first aim of the project was therefore to express a larger fragment of RBBP6 containing 
the RING finger and use analytical size exclusion chromatography to investigate whether it 
formed monomers or homo-dimers. Co-workers in the laboratory had previously expressed 
an N-terminal fragment corresponding to the first 335 residues of RBBP6. It was dubbed R3 
because it contained three recognisable domains: the ubiquitin-like DWNN domain, the zinc 
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finger, and the RING finger. R3 has been shown to be active as an E3 ubiquitin ligase (A. 
Faro, L. Jooste and D.J.R. Pugh, manuscript in preparation). 
 
Two mutations that monomerize the RING finger, N312D and K313E, had previously been 
identified (Kappo et al. 2012). On the assumption that R3 would homo-dimerize more 
strongly than the isolated RING, the next step was to test whether the mutants were still 
able to monomerize R3. If not, it would demonstrate that R3 homo-dimerizes more strongly 
than the isolated RING and homo-dimerisation of R3 may therefore be biologically 
meaningful. The mutants would also represent useful negative controls for investigating the 
requirement for dimerisation on the ubiquitination activity of R3.  
 
3.1.1 Insertion of putative monomerising mutations into the R3 fragment of RBBP6 
The pGEX-R3-6His expression construct, containing cDNA coding for the first 335 residues of 
RBBP6 cloned into the BamHI and XhoI sites of pGEX-6P-2, had been generated previously 
by a co-worker, Dr Andrew Faro. The sequence was codon-optimised for expression in 
bacteria and included a 6His affinity tag inserted between R3 and the XhoI site, for affinity 
purification on nickel sepharose. In order to investigate whether the mutations N312D and 
K313E, along with an additional F313W mutant, were sufficient to abolish the expected 
homo-dimer adopted by the R3 fragment, the same mutations were introduced into the 
pGEX-R3-6His construct. 
 
Table 3.1: Primers designed to generate mutated R3 
Primer Name Sequence 
pGEX-6P-R3-N312D-F 5’-GAC GCA CTG ATT GCT GAC AAA TTT CTG  CGC C-3’ 
pGEX-6P-R3-K313E-F 5’-GCA  CTG ATT GCT AAC GAA TTT CTG CGC CAG G-3’ 
pGEX-6P-R3-F314W-F 5’-CTG ATT GCT AAC AAA TGG CTG CGC CAG GCT GTC-3’ 
The reverse primers are the reverse compliments of these forward primers. 
 
Site-directed mutagenesis was carried out using the QuikChange protocol: briefly, the 
complete closed circular template was amplified using PfuTurbo DNA polymerase (Agilent 
Technologies, Santa Clara, California), which is optimized for long and accurate reads. To 
minimize mutations, the protocol uses only a small number of cycles to amplify a small 
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number of copies and then selects for those few copies using a restriction enzyme, DpnI, 
that only cleaves its consensus sequence, 5´-GATC-3´, when it is methylated or hemi-
methyated on the N6 position of the adenine (5´-Gm6ATC-3´). The template DNA is 
methylated, provided it was expressed in a dam+ E. coli strain, and so is cleaved by the 
enzyme, whereas the PCR amplicons are not methylated, and hence will not be cleaved and 
will transform into a cloning strain of E. coli. 
 
Nine colonies were obtained for N312D, 12 for K313E and 13 for F314W. Plasmid DNA was 
extracted from six colonies for each mutant and four of each mutant were subjected to 
sequencing and found to contain the desired mutation, except two, one from K313E and 
one from F314W. Details of the sequencing can be found in the appendix section. 
 
3.1.2 Bacterial expression and purification of wild type and mutant R3 
Wild type R3 (residues 1-335 of human RBBP6) containing an N-terminal GST and a C-
terminal 6His tag was expressed at 30 °C in E. coli BL21(DE3)pLysS using the pGEX-6P-2 
expression vector. As can be seen from Figure 3.1, panel A, a protein of greater than 70 kDa 
was eluted from the column after addition of reduced glutathione (lanes 7-11), 
accompanied by a number of lower molecular weight species. This is larger than the 
expected size of 64.7 kDa, as determined using the ProtParam server 
(http://web.expasy.org/protparam/); the reason for this is not known, but may have to do 
with the fact that the protein forms a homo-dimer (see below). The isolated RING finger has 
been reported to migrate at almost twice its expected molecular weight (Kappo et al. 2012). 
 
In an attempt to remove the lower MW bands, the fusion protein was subjected to HisTrap 
chromatography using the C-terminal 6His tag. Due to the position of the tag, only proteins 
with an intact C-terminus will be retained and since the C-terminus is more likely to be 
subject to proteolysis than the N-terminus, which is made up of GST, this method may be 
expected to eliminate most of the lower molecular weight bands. 
 
As can be seen from panels B and C of Figure 3.1, GST-R3-6His was retained on the nickel 
sepharose column and eluted in a sharp peak on the chromatogram (panel B, peak 3), 
corresponding to lanes 5-8 on the SDS-PAGE shown in panel C. This produced a significant 
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concentrating of the target protein, which was very convenient. However, there was no 
significant reduction in the fraction of lower molecular weight proteins. The reason for this 
is not clear; however since they co-elute with Full-length GST-R3-6His in both glutathione 
and nickel affinity chromatography, a likely explanation is that the lower MW bands 
correspond to fragments of R3, which dimerize with the full-length protein. 
 
Fractions from Peak 1 in Figure 3.1 panel B were pooled together and GST was removed 
using 3C protease as shown in Figure 3.2, panel A. Cleavage was very efficient, producing a 
band at around 50 kDa, which is likely to correspond to R3-6His, and a stronger band around 
28 kDa, which is likely to correspond to GST. The higher MW band is larger than expected 
for R3-6His (38 kDa, including the 6His tag and the five residues Gly-Pro-Leu-Gly-Ser left over 
after removal of GST using 3C protease), but is it consistent with the earlier observation that 
the fusion protein migrates at a higher molecular weight than expected. In fact, during the 
course of this work R3-6His was observed to migrate at a number of different effective 
molecular weights (data not shown). Size exclusion chromatography was used to remove 
GST after cleavage, as shown in panel B, yielding three well-separated peaks. SDS-PAGE 
analysis (panel C) shows that peak 2 consisted mainly of R3-6His and peak 3 of GST, resulting 
in effective separation of proteins. Fractions making up peak 2 were pooled and used to 
investigate the oligomerisation state of wild type R3 (see below). Using the expression 
constructs generated earlier, the N312D, K313E and F314W mutants were expressed in the 
same way and successfully purified (data not shown). 
 
3.1.3 Expression and purification of the RING finger from RBBP6  
Samples of the isolated RING (249-335 of human RBBP6), wild type, and N312D and K313E 
mutants were also expressed using existing expression constructs, to serve as positive 
controls for the analytical SEC analysis of R3. Previous analysis using NMR showed 
conclusively that the N312D and K313E mutants of the isolated RING are monomeric, 
whereas the wild type is only partially dimeric at NMR concentrations (between 0.2 and 1 
mM). 
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Figure 3.1: Purification of the fusion GST-R3-6His. (A) Purification using a gravity-flow glutathione 
agarose column. Lane M shows the protein molecular weight marker, lane 1 the insoluble protein, 
and lane 2 the soluble (crude) lysate. Lane 3 is the flow through, lanes 4-6 are washes and lane 7-11 
shows fraction eluted from the glutathione-agarose column. Lane 12 shows fraction during NaCl 
wash. (B) Purification using HisTrap chromatography. Peak 1 is the flow through and peak 3 is the 
elute fractions. (C) The SDS-PAGE substantiates the HisTrap chromatogram, lanes 2-4 show the flow 
through (peak 1) and lanes 5-9 shows elution fraction (peak 3). 
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Figure 3.2: Purification of R3-6His after removal of GST. (A) Some in-cell cleavage of the fusion 
protein around the 72 kDa were observed in Lane 1; nevertheless the GST was completely removed 
after cleavage with 3C protease (lane 2) yielding bands around 50 kDa and the 25 kDa corresponding 
to R3 and GST respectively. (B) Size exclusion chromatogram showing clear separation between R3-
6His (peak 2) and GST (peak 3) (C) The Coomassie stained SDS-PAGE of the SEC samples from the 
three peaks, lanes 2-4, lanes 5-8 and lanes 9-14 represented peak 1, 2 and 3, respectively.  
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Panel A of Figure 3.3 shows that large amounts of pure GST-RING were successfully eluted 
from the glutathione agarose column (lanes 6-8). The absence of a prominent band in the 
insoluble fraction (lane 2) confirms that the isolated RING is highly soluble, as reported 
previously (Kappo et al. 2012). After the cleavage of the fusion protein with 3C protease, 
lane 2 of panel B, which is produced recombinantly in our laboratory, yielded the expected 
band at around 15 kDa corresponding to RBBP6-RING, as well as a band corresponding to 
GST at around 27 kDa. It has been observed previously that the RBBP6-RING finger typically 
migrates as a smear between 10 and 20 kDa (Kappo et al. 2012). The significant band at 
around 37 kDa corresponds to un-cleaved fusion protein, showing that cleavage with 3C was 
not 100 % successful. The band around 50 kDa in lane 2 of panel B corresponds to the GST-
3C fusion protein.  
 
Following dialysis to remove free glutathione the cleaved sample was returned to the 
glutathione-agarose column to remove free GST, fusion protein and GST-3C protease (lanes 
7-8), with RBBP6-RING being collected in the flow through (lanes 3-4). This was only partially 
successful, with a significant fraction of GST and fusion protein remaining in lanes 3 and 4 
(see panel C of Figure 3.3).  
 
Remaining GST and GST-RBBP6-RING were successfully removed using size exclusion 
chromatography. Two well-separated peaks were obtained, as shown in the chromatogram 
in panel C, with peak 1 corresponding to GST and peak 2 to RBBP6-RING. Panel C shows that 
the end result was a strong, highly purified sample of RBBP6-RING. Samples of the N312D 
and K313E mutants of RBBP6-RING were prepared similarly from pre-existing expression 
constructs (data not shown).  
 
3.2 Investigation of the oligomeric states of the RING finger and R3 fragments of RBBP6 
Size exclusion chromatography separates molecules based on their effective molecular 
weight. A linear relationship is observed between the elution volume (Ve) and the logarithm 
of the molecular weight, log10(MW), over a range of MW that depends on the beads making 
up the matrix. This relationship can be used to give reasonably good estimates of the 
effective molecular weight of protein by comparing it with a standard curve generated using  
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Figure 3.3: Expression and purification of the RING finger from RBBP6. (A) Cell lysate of the GST 
fusion RING finger was purified using glutathione-agarose column. The large amount of the fusion 
protein at around 37 kDa was expressed; lanes 6-8 show the eluted fraction. Lane 1 shows the 
soluble fraction and lane 2 is the insoluble fraction. Lane 3 is the flow through and lanes 4-5 show 
the washes. (B) Following cleavage of the GST tag, GST was removed using a glutathione-agarose 
column, with the target protein being collected in the flow through. Lane 2 is the sample after 
cleaving, showing bands at around 37 kDa and 15 kDa corresponding to the GST-RING finger and the 
RING finger, and bands around 50 kDa and 25 kDa corresponding to the GST-3C protease and free 
GST, respectively. Lanes 7 and 8 shows the GST tag and fusion protein eluted from the column. This 
step was repeated three times to separate GST and the fusion protein from the protein of interest. 
(C) Size exclusion chromatogram showing clear separation between GST (peak 1) and RBBP6-RING 
(peak 2) (D) SDS-PAGE confirming the peaks. Lanes 2-3 shows fractions from peak 1 and lanes 4-9 
shows fractions from peak 2. 
 
 
 
 
  
42 
 
 
 
Figure 3.4: Protein standards used to estimate molecular weight. (A) Size exclusion chromatogram 
of protein standards shown in different colours. Proteins with molecular weight (MW) above the 
MW range between 3 kDa and 70 kDa of the matrix eluted in or just before the void volume, around 
45 ml. These proteins include Alcohol dehydrogenase (150 kDa) and Beta-amylase (β-amylase) (200 
kDa). (B) Standard curve of elution volume (Ve) against the log (MW) for protein standards. 
Cytochrome C (12.4 kDa), Carbonic Anhydrase (29 kDa) and Albumin (66 kDa), were used to form a 
straight line. While the point that level off, Alcohol dehydrogenase (150 kDa) and Beta (β)-amylase 
(200 kDa) were excluded, including the Blue dextran (2000 kDa).  
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proteins of known molecular weight. This is an effective method of determining whether 
proteins are monomeric, dimeric, or oligomeric in solution. 
 
3.2.1 Calibration of the SEC column 
The proteins listed in Table 3.2 were used to generate a standard curve for a HiLoad 16/60 
Superdex 75 column. The elution volumes are recorded and the chromatogram is shown in 
Figure 3.4, panel A. A graph of Ve vs log (MW) is shown in panel B. The data lie on a straight 
line for the three proteins up to 66 kDa, but for higher molecular weight proteins, the graph 
flattens out. This is as expected, since Superdex 75 is only expected to be linear up to 
approximately 75 kDa. Only the first three points were therefore fitted to a straight line, 
yielding slope m = 35.3 ± 2.8 and y-intercept c = 116.8 ± 4.2. 
 
Table 3.2: Molecular weights and elution volumes for proteins used to construct a 
standard curve  
Protein Standards Molecular 
Weight (kDa) 
Log (Mw) Elution 
Volume  (ml) 
Cytochrome C 12.4 1.09 77.9 
Carbonic anhydrase 29 1.46 65.7 
Albumin 66 1.82 52.3 
Alcohol dehydrogenase 150 2.18 48.0 
β-Amylase 200 2.30 46.2 
Blue dextran 2000 3.30 45.2 
 
3.2.2 SEC analysis of wild type and mutant RBBP6-RING 
RBBP6-RING was previously shown using NMR spectroscopy to form a homo-dimer with a KD 
of around 100 μM (Kappo et al. 2012). This means that at concentrations much above 100 
μM it is expected to be dimeric whereas at concentrations much below 100 μM it is 
expected to be monomeric. The same study showed that two single amino acid 
substitutions within the dimerisation interface - N312D and K313E - were able to 
monomerize RBBP6-RING. Figure 3.5 shows that RBBP6-RING wild type, N312D and K313E 
eluted around 76.35 ml, 82.54 ml, and 82.74 ml respectively. Employing the parameters 
extracted from the standard curve this corresponds to an effective molecular weight of 
13.98 kDa for wild type RING, and 9.34 kDa and 9.23 kDa for N312D and K313E respectively 
(see Table 3.3). 
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The values for the mutants agree well with the expected molecular weights of 9.2 kDa, 
confirming that they are indeed monomers. The value obtained for the effective MW of the 
wild type falls approximately half way between the weights of the monomer and homo-
dimer. This is not a surprise because the loading concentration of approximately 81 µM is of 
the same order as the KD (100 μM) and consequently each molecule is likely to spend part of 
its time on the SEC column as a monomer and part as a dimer. As a result, it is likely to elute 
somewhere between the volumes expected for a monomer and a dimer, which is exactly 
what is observed. These results are therefore consistent with the results of the previous 
NMR study. These results suggest that size exclusion chromatography can be used to 
determine the molecular weight of proteins. However, it is more useful and reliable if 
coupled with multi angle light scattering (SEC-MALS), which overcomes the limitations of 
column calibration and determine the molecular weight of protein directly (Meyer and 
Morgenstern 2003, Lauber et al. 2015). 
 
 
Figure 3.5: Size exclusion chromatogram of the wild type and mutated RING finger from RBBP6. 
Both mutants RING-N312D and K313E eluted at around 80 ml, corresponding to a molecular weight 
(MW) of approximately 9 kDa, showing that they are monomeric. In contrast, the wild type eluted at 
around 76 ml, corresponding to a MW of 14 kDa, which shows that it is partially monomeric and 
partially dimeric in solution, consistent with a previous NMR study.  
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Table 3.3: Determination of the effective molecular weight (MW) of RBBP6-RING  
RBBP6 RING Ve Log MW MW (kDa) 
Wild type (WT) 76.4 1.15 14.0 
N312D 82.5 0.97 9.3 
K313E 82.7 0.96 9.2 
 
3.2.3 SEC analysis of wild type and mutant R3 
Next, we investigated the effective MW of wild type R3 and two mutant forms, N312D and 
K313E. In all cases, the loading concentration was approximately 84-87 µM. The 
chromatogram in Figure 3.6 shows that wild type R3 eluted at approximately 50 ml, which 
corresponds to 77.7 kDa using the calibration discussed earlier. This is consistent with the 
weight of the homo-dimer38 kDa x 2 = 76 kDafrom which we conclude that R3 is 
entirely dimeric under these conditions (see Figure 3.6). Mutants, N312D and K313E eluted 
at essentially the same volume, from which we conclude that the same mutations that 
monomerize the RING are insufficient to monomerize the R3 dimer (see Table 3.5). We 
conclude from this that R3 is a stronger dimer than the isolated RING finger, and we 
therefore expect the KD of the dimerisation to be smaller than the 100 μM measured for the 
RING finger. Whereas an interaction with a KD of 100 μM is unlikely to be physiologically 
significant, since the concentration of RBBP6 is unlikely to reach 100 μM under physiological 
conditions, our results suggest it is possible that isoforms of RBBP6 larger than just the RING 
finger will dimerize sufficiently strongly to be physiologically relevant.  
 
3.3 Expression and purification of the R2 fragment of RBBP6 
The R3 fragment was found to be highly susceptible to proteolysis, as shown above, and so 
we sought to express a smaller fragment that may be more suitable for structural analysis. 
Alignment of RBBP6 orthologues from a number of organisms revealed the presence of a 
poorly conserved and low-complexity region between the DWNN domain and the zinc finger 
domain. This suggested the zinc and RING fingers, a fragment that we dubbed R2 because it 
contains only two domains, may form a structured unit. If so, we would like to investigate 
whether it formed a strong homo-dimer like R3, since that would suggest that R2 contains 
most of the dimerisation interface and that the DWNN domain is not required for 
dimerisation. In addition to the benefits for structural analysis, the proposed fragment may  
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Figure 3.6: Size exclusion chromatogram of the wild type and mutated R3. The wild type and both 
mutants eluted around 50 ml, corresponding to a molecular weight of approximately 78 kDa. This is 
consistent with the weight of the homo-dimer, 74.8 kDa. The mutants were not sufficient to break 
homo-dimerization of the protein.  
 
Table 3.4: Determination of the effective molecular weight (MW) of wild type R3 and two 
mutants 
R3 Ve Log MW MW 
Wild type (WT) 50.07 1.89 77.7 
N312D 49.49 1.91 80.7 
K313E 49.74 1.90 79.3 
 
also be useful for investigating the requirement of dimerisation for ubiquitination and the 
role of the ubiquitin-like DWNN domain in ubiquitination. We had previously shown that R3 
is active as an E3 ligase (A. Faro, L. Jooste and D.J.R. Pugh, manuscript in preparation); 
carrying out similar assays using R2 should show whether the DWNN domain was required 
for ubiquitination activity. 
 
3.3.1 Generation of expression construct for R2-6His  
The C-terminal end of the DWNN domain was at residue 81 and the start of the zinc finger in 
the vicinity of residue 160. Alignment of a number of RBBP6 orthologues showed that the 
region between residues 90 and 140 was poorly conserved and of low complexity, which 
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suggested that this might play the role of a flexible linker. The beginning of R2 was therefore 
chosen at residue 143. Oligonucleotide primers (see Table 3.5) were designed to amplify 
residues 143 – 335 of RBBP6, using a codon-optimised cDNA coding for the R3-6His 
previously synthesised by GenScript Inc. (Piscataway NJ, USA) and supplied in a pUC57 
vector. Since the pET28a vector includes a C-terminal 6His tag that cannot be conveniently 
removed, the primers were designed to exclude the 6His tag in the template, and to 
incorporate an XhoI site in order to utilise the 6His tag in the vector. The forward primer was 
designed to incorporate an NcoI site to eliminate the N-terminal 6His tag present in the 
vector. The beginning of R2 (Asp-Pro-Ile-Asn-) followed immediately after the first four 
residues (Met-Gly-Ser-Ser) expressed from the pET28a promoter. At the C-terminus of R2 (-
Leu-Arg-Lys-Gln) an additional pair of residues (Gly-Ser) was inserted (in addition to the -
Leu-Glu- already present) immediately before the 6His tag in order to ensure that the 6His 
tag was not too close to R2 to interfere with its ability to bind to nickel sepharose. The 
construct was designed to express a 207 amino acid protein with an expected molecular 
weight of 23.0 kDa (ProtParam server http://web.expasy.org/protparam/) (Gasteiger et al. 
2005). 
 
Table 3.5: Oligonucleotide primers designed for the generation of pET28a-R2-6His 
construct 
Primer Name Sequence 
pET28a-R2-F 5’- GAG GCG CCA TGG GCA GCA GCG ACC CGA TCA ACT ACA TGA AA -3’ 
pET28a-R2-R 5’- GAG GCG CTC GAG GCT GCC TTG TTT ACG CAG ACG TTT CGT -3’ 
Bases highlighted in pink and green correspond to NcoI and XhoI restriction sites respectively; blue 
code for the “spacer-residues” Gly-Ser inserted between the C-terminus of R2 and the 6His tag. 
Underlined bases are complimentary to the insert. No stop codon is included so that the 6His tag 
contained in the plasmid will be incorporated into the expressed protein. 
 
Successful generation of the pET28a-R2-6His construct is shown in Figure 3.7. The R2 insert 
was successfully amplified by PCR, yielding a band consistent with the expected size of 
approximately 600 bp (panel A, lane 2). The expression vector and the amplicon were 
digested with NcoI and XhoI to generate complementary sticky ends (panels B and C 
respectively) after which they were ligated and transformed into E. coli. Plasmid DNA from 
putative transformants was digested with NcoI and XhoI to release the insert, as shown in 
panel D. Released fragments of the expected size can be seen in lanes 3, 5, 7, 9 and 11; the  
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Figure 3.7: Generation of pET28a-R2-6His expression constructs. (A) The band at approximately 600 
bp in lane 2 corresponds to the desired R2-6His amplicon and lane 1 is the negative control. (B) 
Digestion of R2 amplicon using both NcoI (lane 2) and Xhol (lane 3), whereby lane 4 is the double 
digested R2 amplicon with the same enzymes, whilst Lane 1 is the undigested R2 amplicon (C) 
Digestion of pET28a expression vector using both NcoI (lane 2) and XhoI (Lane 3) and lane 4 is the 
double digest. Lane 1 is the circular vector. (D) Screening of putative positive colonies: lane 3, 5, 6, 7, 
and 9 are double digests of the recombinant DNA. Lane 1 consists of an R2 amplicon as a control and 
lane 2, 4, 6, 8 and 10 are controls.  
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original PCR amplicon loaded in lane 1 indicates the approximate size of the insert. The DNA 
sequence of the colonies was confirmed by direct DNA sequencing. 
 
3.3.2 SEC analysis of R2 
SEC was used to determine the effective MW of R2 (143-335 of human RBBP6) using a 
loading concentration of approximately 90 µM. Figure 3.11 shows that R2 eluted at around 
58 ml, which corresponds to a MW of 46 kDa (see Table 3.6). A molecular weight of 46 kDa 
agrees very well with the expected MW of homo-dimeric R2: 2x 23 kDa = 46 kDa. We 
conclude that, like R3, R2 forms a strong homo-dimer. This result supports the conclusion 
that the zinc knuckle participates in the homo-dimerisation interface, increasing the affinity 
of the interaction when compared to the isolated RING. It further suggests that the DWNN 
domain may not play a role in the homo-dimerisation, a possibility that warrants further 
investigation.  
 
3.4. In vitro investigation of auto-ubiquitination of the RING finger domain from RBBP6 
Many ubiquitin E3-ligases are able to catalyse ubiquitination of themselves as well as 
substrates, a process known as auto-ubiquitination (Everett et al. 2010). Auto-ubiquitination 
is often used as a convenient proxy for substrate-ubiquitination, both because it is easier to 
study in vitro and because substrates for a particular E3 are not always known.  
 
RBBP6 has been shown to be able to ubiquitinate substrates such as YB-1 (Chibi et al. 2008), 
zBTB38 (Miotto et al. 2014) and p53 (Dr A. Faro, Ms L. Jooste and Dr D.J.R. Pugh, 
unpublished data) but prior to this work the question of whether RBBP6 could auto-
ubiquitinate itself had not been investigated fully. Preliminary un-published results obtained 
by a co-worker suggested that the isolated RING finger domain was able to auto-
ubiquitinate itself in vitro, leading to degradation in the proteasome (Dr A. Faro and Dr 
D.J.R. Pugh, manuscript in preparation); auto-ubiquitination of RING fingers has been 
previously reported by Everett and co-workers (Everett et al. 2010). We therefore decided 
to attempt to replicate the result using wild type RBBP6-RING as well as the monomerising 
mutants. Homo-dimerization is known to be a requirement for ubiquitination activity of 
many E3s, so it would be of interest to determine whether the mutants catalysed auto-
ubiquitination as efficiently as wild type.  
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Figure 3.8: Expression and purification of R2 using a nickel sepharose column. Protein retained by 
the column and subsequently eluted can be seen in lanes 6-8.  
 
 
Figure 3.9: Size exclusion chromatography of R2. R2 protein eluted at around 58 ml, which 
corresponds to a molecular weight of 46 kDa. The molecular weight of 46 kDa agreed very well with 
the expected homo-dimeric MW of 46.0 kDa (2x 23.0 kDa). 
 
Table 3.6: Determination of the effective molecular weight (MW) of R2 
R2 Ve Log MW MW 
Wild type 58.01 1.67 46.3 
 
Bacterially expressed wild type RBBP6-RING was subjected to in vitro ubiquitination assays 
using the following enzymes kindly supplied by co-workers in the laboratory, Ms L. Jooste 
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and Dr A. Faro: human E1, the E2s UbcH1, UbcH5a, UbcH5b, UbcH5c, UbcH6, UbcH7 and 
UbcH13 and HA-tagged ubiquitin. The protocol set out in Section 2.11, which makes use of 
the high stability of ubiquitin at low pH to precipitate other proteins, was required since HA-
ubiquitin contained neither GST- nor 6His-tag for affinity purification. Ubiquitinated RBBP6-
RING was detected by Western Blotting with antibodies targeting ubiquitin, rather than the 
more common strategy of targeting the HA tag with anti-HA antibodies.  
 
Panel A of Figure 3.10 shows that wild type RBBP6-RING is able to auto-ubiquitinate itself in 
the presence of E1, E2 and ubiquitin (lane 6), but not when ubiquitin is omitted (lane 5), all 
E2s are omitted (lane 4) or E1 is omitted (lane 3). The ladder in lane 6 extends right up to 
the top of the gel, significantly past the top MW marker band at 150 kDa. Since RBBP6-RING 
contains only five lysine residues, mono-ubiquitination at each site would account for only 
50 kDa, suggesting that the ladder corresponds to the formation of poly-ubiquitin chains. It 
is perhaps of concern that free ubiquitin is not also observed, migrating at 10 kDa, in all 
lanes to which it was added; i.e. lanes 2-4 of panels A, B and C. This is most likely to be the 
result of under-exposure of the image due to the heavy signal in lane 6; however, it 
warrants further investigation. 
 
Panels B and C show that the N312D and K313E mutants are also able to auto-ubiquitinate 
themselves, ruling out the hypothesis that homo-dimerisation is required for ubiquitination. 
However the ubiquitination appears not to extend as far up the gel as with the wild type, 
which may be evidence that monomeric RBBP6-RING auto-ubiquitinates itself less efficiently 
or that it comprises mono-ubiquitination rather than poly-ubiquitination. Although RBBP6-
RING was not demonstrated to self-ubiquitinate as an E3 ligase in previously studies. 
Immediate-early protein ICP0 of herpes simplex virus type 1 (HSV-1)-RING has been shown 
to self-ubiquitinate (Everett et al. 2010). 
 
One of the most well known characteristics of poly-ubiquitination is its ability to catalyse 
degradation of the substrate protein in the 26S proteasome. This is most closely associated 
with lysine 48-linked chains, although other modes of linkage have also been reported to 
catalyse degradation (Zhang et al. 2013). In order to test whether the auto-ubiquitination of 
the RING finger rendered it susceptible to degradation, intact proteasomes precipitated 
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from mammalian cell lysates (a kind gift from a co-worker in the laboratory, Ms Tephney 
Hutchinson) were added to the reactions. Panel D of Figure 3.10 shows that addition of 
proteasome caused the high molecular weight ladder to disappear dramatically (compare 
lanes 1 and 2), suggesting that the RING has been degraded by the proteasome. The effect is 
less dramatic in the case of the mutants (compare lanes 3 and 4 and lanes 5 and 6 
respectively), but it is still present.  
 
A possible alternative explanation for the effect seen in panel D is that other factors such as 
de-ubiquitinating proteases (DUBs) have been inadvertently added to the reaction along 
with 26S proteasome. To control for this effect, an improvement of this assay would involve 
the addition of MG132 along with the proteasomal preparation. Since MG132 specifically 
inhibits the proteasome and not other proteases, if it were able to rescue the high 
molecular weight ladders it would constitute conclusive evidence that the disappearance of 
the bands was indeed due to degradation of RBBP6-RING by the proteasome.  
 
3.5 In-vitro investigation of a putative interaction between the RING finger domains of 
RBBP6 and MDM2  
RBBP6 has been reported to promote ubiquitination of p53 by MDM2 in vivo, leading to 
suppression of p53 (Li et al., 2007). The authors of that report proposed that RBBP6 acts as a 
scaffold on which the complex of MDM2 and p53 assembles, involving the p53-binding 
domain identified towards the C-terminus of RBBP6 (Simons et al, 1997). However, 
preliminary results from our laboratory suggest that the R3 fragment of RBBP6 is sufficient 
to promote ubiquitination of p53 by MDM2. A possible alternative explanation is that   
RBBP6 forms a hetero-dimer with MDM2 through their respective RING finger domains, 
similar to the hetero-dimer formed between MDM2 and MDMX. To test this hypothesis we 
decided to express RBBP6-RING and MDM2-RING in bacteria and investigate whether they 
interacted in vitro using GST pull down assays. If so, this would lay the foundation for future 
NMR-based studies of the RING-RING complex. 
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Figure 3.10: Auto-ubiquitination and proteasomal degradation of the isolated RING finger from 
RBBP6 in vitro. (A) Wild type RBBP6-RING is heavily ubiquitinated in the presence of ubiquitin, E1 
and E2 enzymes (lane 6), but not when ubiquitin is omitted (lane 5), the E2 is omitted (lane 4) or the 
E1 is omitted (lane 3). Since no other E3 is present in this in vitro assay, it can only be auto-
ubiquitination. Monomerising mutations N312D (B) and K131E (C) are similarly able to auto-
ubiquitinate themselves, although possibly less efficiently than wild type. Polyclonal antibody sc-
9133 from Santa Cruz Biotechnology Inc. (Santa Cruz CA, USA) raised against ubiquitin was used to 
detect the ubiquitinated RING. (D) Addition of intact proteasomes purified from human cell lysates 
dramatically reduced the higher molecular weight laddering, indicating that the auto-ubiquitinated 
RING had been degraded by the proteasomecompare lanes 1 (minus proteasome) and lane 2 (plus 
proteasome). A similar result was observed for the N312D mutant (lanes 3 and 4) and the K313E 
mutant (lanes 5 and 6), although the degradation did not appear to be as efficient as for wild type. A 
polyclonal antibody (sc-9133, Santa Cruz, CA, USA) raised against ubiquitin was used to detect 
ubiquitinated RING. 
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3.5.1 Expression and purification of the RING domains of RBBP6 and MDM2 
RBBP6-RING was expressed as a GST-fusion protein and the GST tag was removed following 
purification, as described in Section 3.1.3. Constructs coding for the C-terminal RING finger 
domain of MDM2 (residues 438 to 491), fused to either a GST or a 6His tag (GST-MDM2-
RING or MDM2-RING-6His respectively) had been previously generated by co-workers in the 
laboratory. Expression and purification of GST-MDM2-RING using a glutathione-affinity 
column is shown in Figure 3.11; significant quantities of pure protein were eluted from the 
column (panel A, lanes 6-8).  
 
The fusion protein (panel A, lane 6-8, pooled together) (panel B, lane 1) was successfully 
cleaved using 3C protease, but relative to the amount of GST, the yield of MDM2-RING was 
significantly less than expected (panel B, lane 2). However, MDM2-RING has been reported 
to form oligomers including dimer and higher-order complexes in vivo (Cheng et al. 2011). 
Therefore, we suspect this resulted in high molecular weight ladders on SDS PAGE gels, 
which are difficult to observe, making the protein seem to disappear. Panel C shows 
purification of 6His-MDM2-RING using nickel ion affinity chromatography. Although it is not 
as clean as GST-MDM2-RING, a significant band around 15 kDa can be seen in lane 9. 
 
3.5.2 Pull down assays involving the RING domains of RBBP6 and MDM2 
GST-MDM2-RING was immobilized on glutathione-conjugated agarose beads and co-
precipitation of RBBP6-RING was detected using a polyclonal antibody raised against 
bacterially expressed RBBP6-RING (produced in the laboratory of Prof Bellstedt, 
Biochemistry Department, Stellenbosch University). In colloquial terms, GST-MDM2-RING 
served as the “bait” and RBBP6-RING as the “prey”. Note that although RBBP6-RING was 
originally expressed as a fusion with GST, GST was removed prior to the assay; otherwise, it 
would itself have been precipitated by the pull down procedure. 
 
The band at the bottom of lane 4 corresponds to RBBP6-RING and shows that MDM2-RING 
is able to co-precipitate RBBP6-RING, whereas neither GST alone (lane 3), nor the 
glutathione-conjugated agarose alone (lane 2), were able to. The faint band at the bottom 
of lane 1 corresponds to the original diluted sample of RBBP6-RING, which had not been 
subjected pull down, which serves to confirm that the co-precipitated band in lane 4 is  
 
 
 
 
  
55 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.11: Expression and purification of MDM2 RING. (A) GST-MDM2 RING fusion retained in the 
glutathione-agarose column and eluted as indicated in lanes 6-8. The expression level of the protein 
in E.coli was quite good. Lane M: MW marker, lane 1: insoluble fraction, lane 2: soluble fraction, lane 
3: flow through and lane 4-5: washes. (B) The fusion protein was successfully cleaved using 3C 
protease. M: MW marker, lane 1: before cleaving, lane 2: after cleaving, lane 3: flow through, lane 4: 
wash. (C) 6His-MDM2 RING-6 purified in Ni column, most protein eluted in lane 9. Lane M: MW 
marker, Lane 1: insoluble fraction, lane 2: soluble fraction, lane 3: flow through and lane 4-6: 
washes. 
 
 
 
 
  
56 
 
indeed RBBP6-RING. The higher molecular weight bands detected by anti-RBBP6-RING 
antibody in lane 4 of Figure 3.12 may be contaminant of un-cleaved fusion protein, as well 
as smears indicating oligomerisation of the RING. 
 
The pull-down assay is an in vitro method used to determine a physical interaction between 
MDM2-RING and RBBP6-RING. Techniques such as yeast two-hybrid, GST pull-down, and co-
immunoprecipitation, are usually used together to determine or verify the interactions of 
protein (Agarwal et al. 2008). Thus, this pull-down assay serves as an initial screening assay 
for identifying interaction between MDM2-RING and RBBP6-RING using co-
immunoprecipitation and yeast two-hybrid. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.12: GST-MDM2-RING is able to precipitate RBBP6-RING. RBBP6-RING was co-precipitated 
by GST-MDM2-RING (lane 4), but not by GST alone (lane 3). It was also not precipitated by the 
glutathione-agarose alone (lane2). RBBP6-RING was detected using a RBBP6 polyclonal antibody 
(produced in the laboratory of Prof Bellstedt, Biochemistry Department, Stellenbosch University) 
raised against bacterially-expressed RING domain. 
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Chapter 4: Conclusions and outlook 
 
4.1 Generation of shortenings of RBBP6 and investigation of their oligomeric states 
In vitro analysis of the structure and ubiquitination activity of Retinoblastoma Binding 
Protein 6 (RBBP6) is dependent on efficient over-expression of RBBP6 in bacteria. Given the 
large size, the apparent modular nature of the protein and predictions that large parts of 
the protein are intrinsically unstructured, identification of fragments of RBBP6 that are large 
enough to contain the interesting activities such as ubiquitination, while at the same time 
small enough to be efficiently expressed, is essential. Prior to this work, a fragment denoted 
“R3” spanning the first 335 residues of RBBP6, and containing the DWNN, zinc finger and 
RING finger, had been successfully expressed in bacteria and shown to have E3 
ubiquitination ligase activity. Many E3 ubiquitin-ligases have been found to form homo-
dimers, and dimerisation is suspected to play a role in their catalytic activity. Previous 
results using protein Nuclear Magnetic Resonance Spectroscopy (NMR) showed that the 
RING finger domain of RBBP6 forms weak homo-dimers in solution, but that this could be 
effectively disrupted by single amino acid substitutions N312D and K313E (Kappo et al. 
2012). The first aim of this work was to use analytical size exclusion chromatography (SEC) 
to investigate the oligomeric state of R3 and the corresponding mutants.  
 
Before testing R3, a benchmarking study was carried out on the isolated RING finger and the 
above mutants. As expected both mutants were found to be monomeric, with apparent 
molecular weights very close to values (9 kDa) expected based on the primary sequence. 
The apparent MW of wild type RING, however, was found to be larger (14 kDa), consistent 
with the NMR-derived result that the RING is a mixture of homo-dimer and monomer at 
these concentrations.  
 
In contrast, SEC showed that wild type R3 forms a strong homo-dimer, with most of the 
molecules forming part of homo-dimers, but that the N312D and K313E mutations are not 
sufficient to disrupt the homo-dimer. We conclude from this that the interface formed by R3 
is larger than that formed by the isolated RING finger, and must therefore include parts of 
R3 outside the RING finger domain. It also suggests that the KD of the dimerisation is smaller 
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than the 100 μM measured for the RING finger domain. This increases the likelihood that 
RBBP6 is dimeric under physiological conditions. 
 
The above result posed the question: Which part of R3, in addition to the RING, formed part 
of the interface: the DWNN domain or the zinc finger? To address this question we 
attempted to design a further shortening of R3 excluding the DWNN domain. Based on 
inspection of an alignment of RBBP6 orthologues a start site of residue 143 was selected, 
between the end of the DWNN domain (residue 81) and the beginning of the zinc finger 
domain (residue 160). This fragment, denoted R2 because it contained 2 of the three 
domains identified in R3, was cloned into a pET28a vector so that it would be expressed 
with a C-terminal 6His affinity tag. The protein was successfully over-expressed in E. coli and 
shown, like R3, to form a strong homo-dimer. This suggests that the DWNN domain does 
not form part of the interface, nor is it required for correct folding of R2. Combined with 
results obtained by co-workers that R2 is able to catalyse ubiquitination as efficiently as R3, 
this suggests that R2 may be a more convenient system for structural investigation of the 
ubiquitination activity of RBBP6 than R3.  
 
This study has laid the groundwork for future NMR-based investigation of the R2 fragment 
and the homo-dimer interface. Expression and purification of R2 should be optimised to 
produce as much protein as possible while minimising degradation as much as possible. 15N-
and 13C-enriched samples should be expressed by growing the bacteria on minimal media 
supplemented with 15N-ammonium chloride and 13C-glucose as the sole nitrogen and carbon 
sources respectively. Assignment of backbone residues will be carried out using standard 
triple resonance experiments and residues forming part of a rigid structure (as opposed to 
flexible regions) will be determined using a 15N-NOE spectrum. If necessary, flexible regions 
will be removed from the ends of the fragment and expression of the final construct will be 
optimised for NMR-based investigation of the structure of the homo-dimer. 
 
4.2 Auto-ubiquitination of the isolated RING finger of RBBP6  
Additional investigations were carried out using fragments of RBBP6 expressed for the 
above study. Auto-ubiquitination of E3s by themselves is a useful proxy for substrate 
ubiquitination, especially when it comes to identifying associated E2 enzymes and whether 
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the ubiquitination is poly- or mono-ubiquitination, and the mode of linkage of poly-ubiquitin 
chains. Prior to this project there was no published report of auto-ubiquitination of RBBP6 
although our own preliminary data suggested that it does happen, leading to degradation in 
the proteasome. To our surprise, we found significant auto-ubiquitination of both wild type 
and monomeric RBBP6-RING in in vitro studies. Auto-ubiquitination of an isolated RING 
finger in vitro has been reported previously (Everett et al. 2010), but to our knowledge that 
is the only previous report. Auto-ubiquitination was observed not only with wild type, but 
also with the monomeric mutants N312D and K313E, although it is possible that auto-
ubiquitination with the mutants is less efficient than with wild type. We deduce that auto-
ubiquitination of the RBBP6 RING finger does not require homo-dimerisation, although it is 
possible that it is more efficient when the RING is dimeric. Importantly, the higher molecular 
weight species were significantly reduced when purified human proteasome was added, 
from which we conclude that the ladders represent poly-ubiquitination rather than multiple 
mono-ubiquitination, and that the chains are lysine48-linked. To our knowledge this is the 
first time that ubiquitin-catalysed degradation of a RING finger has been demonstrated in 
vitro. 
 
An alternative explanation for the disappearance of the ladders is that they were removed 
by de-ubiquitinating enzymes (DUBs) co-precipitated with the proteasome. In order to 
eliminate this possibility the assay needs to be repeated adding controls in which the 
proteasome inhibitor MG132 is pre-incubated with the lysate before addition of RBBP6-
RING; if MG132 rescues the auto-ubiquitination then we can conclude that auto-
ubiquitination of RBBP6-RING targets it for degradation in the proteasome.  
 
4.3 Investigation of a possible interaction between the RING fingers of RBBP6 and MDM2 
The final part of the thesis describes investigation of the interaction between the RING 
fingers of RBBP6 and MDM2 in vitro. The investigation was prompted by unpublished data 
from co-workers in our laboratory showing that the R3 fragment of RBBP6 is sufficient to 
activate MDM2 to catalyse poly-ubiquitination of p53; this raises the question of whether 
MDM2 hetero-dimerizes with RBBP6 through their respective RING finger domains in the 
same way that it hetero-dimerizes with MDMX. To test this model, the RING fingers from 
RBBP6 and MDM2 were expressed in bacteria and used in a GST pull down assay; GST-
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MDM2-RING (the bait) was precipitated with glutathione-conjugated agarose beads and the 
presence of co-precipitated RBBP6-RING (the prey) was detected using a poly-clonal 
antibody raised against the RING finger of RBBP6. Our results show a clear interaction, 
which is significant when compared to background. 
 
Attempts to repeat this assay the other way aroundprecipitating GST-RBBP6-RING and 
detecting with an antibody against MDM2-RINGfailed because the anti-MDM2-RING 
antibody was found to have been raised against the N-terminus of MDM2 and therefore did 
not recognise the RING finger domain of MDM2. This will therefore need to be repeated. 
Future repeats will take advantage of HA-tagged forms of RBBP6-RING and MDM2-RING, 
which have become available in the laboratory, for clean detection of co-precipitated 
proteins using anti-HA antibodies.  
 
Use of isolated MDM2-RING as prey has been found to be problematic due to the poor 
stability of the fragment. Repeats will therefore be done using GST-MDM2-RING; in that 
case RBBP6-RING will be used as bait instead of GST-RBBP6-RING, since GST is well known to 
form homo-dimers. That in turn will necessitate immunoprecipitation of the bait rather than 
GST pull down, using either an anti-RBBP6-RING antibody or an anti-HA antibody combined 
with the HA-tagged form of the bait. Detection of GST-MDM2-RING would be most easily 
carried out using an anti-GST antibody. 
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Appendix: Analysis of DNA sequencing of R3 mutants 
 
cgcaccgccctgctggaatcggacgaacatacctgcccgacgtgtcaccaaaatgatgtt 
 R  T  A  L  L  E  S  D  E  H  T  C  P  T  C  H  Q  N  D  V  
agtccggacgcactgattgctaacaaatttctgcgccaggctgtcaataacttcaaaaac 
 S  P  D  A  L  I  A  N  K  F  L  R  Q  A  V  N  N  F  K  N  
gaaacgggctacacgaaacgtctgcgtaaacaa 
 E  T  G  Y  T  K  R  L  R  K  Q 
Translated DNA sequence indicating the three mutated residues: asparagine (N), lysine (K) 
and phenylalanine (F). 
 
N312D 
A 
Query  1737  AAAGATATCATGACGGACGCAGTGGTTATTCCGTGCTGTGGTAATTCATATTGCGATGAA  1796 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  284   AAAGATATCATGACGGACGCAGTGGTTATTCCGTGCTGTGGTAATTCATATTGCGATGAA  225 
 
Query  1797  TGTATCCGCACCGCCCTGCTGGAATCGGACGAACATACCTGCCCGACGTGTCACCAAAAT  1856 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  224   TGTATCCGCACCGCCCTGCTGGAATCGGACGAACATACCTGCCCGACGTGTCACCAAAAT  165 
 
Query  1857  GATGTTAGTCCGGACGCACTGATTGCTAACAAATTTCTGCGCCAGGCTGTCAATAACTTC  1916 
             ||||||||||||||||||||||||||| |||||||||||||||||||||||||||||||| 
Sbjct  164   GATGTTAGTCCGGACGCACTGATTGCTGACAAATTTCTGCGCCAGGCTGTCAATAACTTC  105 
 
Query  1917  AAAAACGAAACGGGCTACACGAAACGTCTGCGTAAACAAcatcatcatcatcatcatTAA  1976 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  104   AAAAACGAAACGGGCTACACGAAACGTCTGCGTAAACAACATCATCATCATCATCATTAA  45 
 
Query  1977  TAACTCGAGCGGCCGCATCGTGACTGACTGACGATCTGCCTCGCG  2021 
             ||||||||||||||||||||||||||||||||||||||| ||||| 
Sbjct  44    TAACTCGAGCGGCCGCATCGTGACTGACTGACGATCTGC-TCGCG  1 
 
B 
 
(A) Query represents the expected sequence of the wild type and the subject (Sbjct) an 
experimental sequence read from the mutant construct. The mutated codon is shown in 
red. AAC in the wild type codes for asparagines (N) and GAC in the mutant for aspartic acid 
(D). (B) DNA sequencing traces were generated using SnapGene (GSL Biotech; available 
at snapgene.com): Sequencing was carried out from the 3’-end and hence the trace 
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corresponds to the reverse compliment of Sbjct- an arrow indicates the reverse codon of 
GAC. 
 
K313E 
A 
Query  1747  TGACGGACGCAGTGGTTATTCCGTGCTGTGGTAATTCATATTGCGATGAATGTATCCGCA  1806 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  280   TGACGGACGCAGTGGTTATTCCGTGCTGTGGTAATTCATATTGCGATGAATGTATCCGCA  221 
 
Query  1807  CCGCCCTGCTGGAATCGGACGAACATACCTGCCCGACGTGTCACCAAAATGATGTTAGTC  1866 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  220   CCGCCCTGCTGGAATCGGACGAACATACCTGCCCGACGTGTCACCAAAATGATGTTAGTC  161 
 
Query  1867  CGGACGCACTGATTGCTAACAAATTTCTGCGCCAGGCTGTCAATAACTTCAAAAACGAAA  1926 
             |||||||||||||||||||| ||||||||||||||||||||||||||||||||||||||| 
Sbjct  160   CGGACGCACTGATTGCTAACGAATTTCTGCGCCAGGCTGTCAATAACTTCAAAAACGAAA  101 
 
Query  1927  CGGGCTACACGAAACGTCTGCGTAAACAAcatcatcatcatcatcatTAATAACTCGAGC  1986 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  100   CGGGCTACACGAAACGTCTGCGTAAACAACATCATCATCATCATCATTAATAACTCGAGC  41 
 
Query  1987  GGCCGCATCGTGACTGACTGACGATCTGCCTCGCG  2021 
             ||||||||||||||||||||||||||||| ||||| 
Sbjct  40    GGCCGCATCGTGACTGACTGACGATCTGCTTCGCG  6 
 
B 
 
(A) Query represents the expected sequence of the wild type and the subject (Sbjct) an 
experimental sequence read from the mutant construct. The mutated codon is shown in 
red. AAA in the wild type codes for lysine (K) and GAA in the mutant for glutamic acid (E). (B) 
DNA sequencing traces were generated using SnapGene (GSL Biotech; available 
at snapgene.com): Sequencing was carried out from the 3’-end and hence the trace 
corresponds to the reverse compliment of Sbjct- an arrow indicates the reverse codon of 
GAA. 
 
F314W 
A 
Query  1734  TGTAAAGATATCATGACGGACGCAGTGGTTATTCCGTGCTGTGGTAATTCATATTGCGAT  1793 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  288   TGTAAAGATATCATGACGGACGCAGTGGTTATTCCGTGCTGTGGTAATTCATATTGCGAT  229 
 
Query  1794  GAATGTATCCGCACCGCCCTGCTGGAATCGGACGAACATACCTGCCCGACGTGTCACCAA  1853 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
 
 
 
 
  
71 
 
Sbjct  228   GAATGTATCCGCACCGCCCTGCTGGAATCGGACGAACATACCTGCCCGACGTGTCACCAA  169 
 
Query  1854  AATGATGTTAGTCCGGACGCACTGATTGCTAACAAATTTCTGCGCCAGGCTGTCAATAAC  1913 
             |||||||||||||||||||||||||||||||||||||  ||||||||||||||||||||| 
Sbjct  168   AATGATGTTAGTCCGGACGCACTGATTGCTAACAAATGGCTGCGCCAGGCTGTCAATAAC  109 
 
Query  1914  TTCAAAAACGAAACGGGCTACACGAAACGTCTGCGTAAACAACATCATCATCATCATCAT  1973 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  108   TTCAAAAACGAAACGGGCTACACGAAACGTCTGCGTAAACAACATCATCATCATCATCAT  49 
 
Query  1974  TAATAACTCGAGCGGCCGCATCGTGACTGACTGACGATCTGC  2015 
             |||||||||||||||||||||||||||||||||||||||||| 
Sbjct  48    TAATAACTCGAGCGGCCGCATCGTGACTGACTGACGATCTGC  7 
 
B 
(A) Query represents the expected sequence of the wild type and the subject (Sbjct) an 
experimental sequence read from the mutant construct. The mutated codon is shown in 
red. TTT in the wild type codes for phenylalanine (F) and TGG in the mutant for tryptophan 
(W). (B) DNA sequencing traces were generated using SnapGene (GSL Biotech; available 
at snapgene.com): Sequencing was carried out from the 3’-end and hence the trace 
corresponds to the reverse compliment of Sbjct- an arrow indicates the reverse codon of 
TGG. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
